



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number

TO: Dwayne C Jones
Location: 3b87 / 3c70
Wednesday, May 10, 2006
Art Unit: 1614
Phone: 571-272-0578
Serial Number: 10 / 528114

From: Jan Delaval
Location: Biotech-Chem Library
Remsen 1a51
Phone: 571-272-2504

jan.delaval@uspto.gov

Search Notes

FOR OFFICIAL USE ONLY

ACCESS DB #

185493

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Dwayne C. Jones Examiner #: 71299 Date: 16 APR 06
Art Unit: 1614 Phone Number: 2-0578 Serial Number: 10/528/119
Location (Bldg/Room#): 3B97 (Mailbox #): SC 70 Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: see attached cover sheet ME

Inventors (please provide full names): _____

Earliest Priority Date: 16 SEP 2002

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search Jurney 1,4,5-7

STAFF USE ONLY

Searcher: C. Jan

Searcher Phone #: 22504

Searcher Location: _____

Date Searcher Picked Up: 5/10/06

Date Completed: 5/10/06

Searcher Prep & Review Time: 30

Online Time: 60

Type of Search

____ NA Sequence (#)

____ AA Sequence (#)

☒ Structure (#)

☒ Bibliographic

____ Litigation

____ Fulltext

____ Other

Vendors and cost where applicable

☒ STN _____ Dialog

____ Questel/Orbit _____ Lexis/Nexis

____ Westlaw _____ WWW/Internet

____ In-house sequence systems

____ Commercial _____ Oligomer _____ Score/Length

____ Interference _____ SPDI _____ Encode/Transl

____ Other (specify)



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact **the searcher or contact:**

Mary Hale, Information Branch Supervisor
22507, Remsen 1d86

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library CM1 – Circ. Desk



```
=> fil reg
FILE 'REGISTRY' ENTERED AT 11:24:39 ON 10 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

```
STRUCTURE FILE UPDATES:    9 MAY 2006  HIGHEST RN 883631-57-0
DICTIONARY FILE UPDATES:  9 MAY 2006  HIGHEST RN 883631-57-0
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.


```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> d sta que 149
L47          STR
N @22      O @23
```



```
REP G1=(3-3) CH2
VAR G2=22/23
NODE ATTRIBUTES:
CONNECT IS M1 RC AT 22
CONNECT IS M1 RC AT 23
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
```

```
GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
```

NUMBER OF NODES IS 21

STEREO ATTRIBUTES: NONE

L49 756 SEA FILE=REGISTRY CSS FUL L47

100.0% PROCESSED 17708 ITERATIONS

756 ANSWERS

SEARCH TIME: 00.00.01

=> d his

(FILE 'HOME' ENTERED AT 10:51:31 ON 10 MAY 2006)
SET COST OFF

FILE 'HCAPLUS' ENTERED AT 10:51:37 ON 10 MAY 2006

E HORROBIN/AU
L1 586 S E5,E8,E12-E16
E AYTON/AU
L2 2 S E4
E CLARKSON S/AU
L3 29 S E3-E6,E13
L4 8204 S EICOSAPENTAENOIC ACID OR EICOSAPENTAENOATE

FILE 'REGISTRY' ENTERED AT 10:53:31 ON 10 MAY 2006

L5 1 S 10417-94-4
E C20H30O2/MF
L6 17 S E3 AND 5 8 11 14 17
L7 8 S L6 AND EICOSAPENTAENOIC ACID
L8 6 S L7 NOT LABELED
SEL RN
L9 160 S E1-E6/CRN
L10 6 S L5,L8

FILE 'HCAPLUS' ENTERED AT 10:56:25 ON 10 MAY 2006

L11 9679 S L10
L12 652 S ICOSAPENT OR ICOSAPENTAENOIC ACID OR ICOSAPENTAENOATE OR TIMN
L13 12866 S L4,L11,L12
L14 100 S L9
L15 145 S L1-L3 AND L13
L16 12 S L1-L3 AND L14
L17 146 S L15,L16
E ANOREXIA/CT
E E3+ALL
L18 2355 S E2,E3
L19 7622 S ANOREX? OR ANOREX?(S)NERVOSA?
E BULIMIA/CT
E E3 ALL
E BULIMIA/CT
E E3+ALL
L20 932 S E1,E2
L21 1171 S BULIMI?
E EATING DISORDER/CT
E E4+ALL
L22 1983 S E2
L23 1432 S E1
L24 4 S L1-L3 AND L18-L23
L25 1 S L24 AND L17
L26 3 S L24 NOT L25
L27 1 S L26 AND 141:105641/DN

L28 2 S L25,L27
L29 54 S L17 AND P/DT
E BODY WEIGHT/CT
L30 22053 S E3-E5
E E3+ALL
L31 64675 S E2 OR E5+OLD,NT OR E6+OLD,NT OR E7+OLD,NT OR E8+OLD,NT
L32 475 S L13 AND L30,L31
L33 22 S L32 AND L18-L23

FILE 'REGISTRY' ENTERED AT 11:04:16 ON 10 MAY 2006

L34 1 S 25378-27-2
L35 17 S 25378-27-2/CRN

FILE 'HCAPLUS' ENTERED AT 11:04:46 ON 10 MAY 2006

L36 1055 S L34 OR L35
L37 2 S L36 AND L18-L23
L38 30 S L36 AND L30,L31
L39 2 S L37 AND L38
L40 22 S L33,L39
L41 11 S L1-L3 AND L36
L42 0 S L41 AND L39
L43 0 S L41 AND L40
SEL AN L40 4 7-9 12 16-21
L44 11 S L40 AND E1-E22
L45 13 S L28,L44
L46 13 S L45 AND L1-L4,L11-L33,L36-L45

FILE 'REGISTRY' ENTERED AT 11:14:19 ON 10 MAY 2006

L47 STR
L48 36 S L47 CSS
L49 756 S L47 CSS FUL
SAV L49 JONES528/A
L50 590 S L49 NOT L9,L10

FILE 'HCAPLUS' ENTERED AT 11:21:15 ON 10 MAY 2006

L51 712 S L50
L52 1 S L51 AND L18-L23
L53 7 S L51 AND L30,L31
L54 8 S L52,L53
L55 0 S L46 AND L51

FILE 'REGISTRY' ENTERED AT 11:24:39 ON 10 MAY 2006

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 11:24:51 ON 10 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 May 2006 VOL 144 ISS 20
 FILE LAST UPDATED: 9 May 2006 (20060509/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d 146 all hitstr tot

L46 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:136529 HCAPLUS
 DN 142:212406
 ED Entered STN: 17 Feb 2005
 TI Method for treating cachexia with RXR retinoid ligands
 IN Jiang, Guang Liang; Yuan, Yang-Dar; Chandraratna, Roshantha A.
 PA Allergan, Inc., USA
 SO PCT Int. Appl., 173 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K0031-00
 CC 1-12 (Pharmacology)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005013949	A2	20050217	WO 2004-US25564	20040806
	WO 2005013949	A3	20050915		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004263156	A1	20050217	AU 2004-263156	20040806
	CA 2535260	AA	20050217	CA 2004-2535260	20040806
PRAI	US 2003-493138P	P	20030807		
	US 2003-533734P	P	20031231		
	WO 2004-US25564	W	20040806		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005013949	ICM	A61K0031-00
	IPCI	A61K0031-00 [ICM,7]
	IPCR	A61K0031-185 [I,C]; A61K0031-192 [I,A]; A61K0031-196 [I,A]; A61K0031-341 [I,A]; A61K0031-341 [I,C]; A61K0031-343 [I,A]; A61K0031-343 [I,C]; A61K0031-381 [I,A]; A61K0031-381 [I,C]; A61K0031-385 [I,A]; A61K0031-385 [I,C]; A61K0031-44 [I,A]; A61K0031-44 [I,C]; A61K0031-505 [I,A]; A61K0031-505 [I,C]
	ECLA	A61K031/192; A61K031/196; A61K031/341; A61K031/343; A61K031/381; A61K031/385; A61K031/44; A61K031/505
AU 2004263156	IPCI	A61K0031-185 [I,C]; A61K0031-341 [I,C]; A61K0031-343 [I,C]; A61K0031-381 [I,C]; A61K0031-385 [I,C]; A61K0031-44 [I,C]; A61K0031-505 [I,C]; A61P0003-00

[I,C]; A61P0025-00 [I,C]; A61P0035-00 [I,C];
A61K0031-192 [I,A]; A61K0031-196 [I,A]; A61K0031-341
[I,A]; A61K0031-343 [I,A]; A61K0031-381 [I,A];
A61K0031-385 [I,A]; A61K0031-44 [I,A]; A61K0031-505
[I,A]; A61P0003-00 [I,A]; A61P0025-00 [I,A];
A61P0035-00 [I,A]
CA 2535260 IPCI A61K0031-192 [I,A]; A61K0031-196 [I,A]; A61K0031-341
[I,A]; A61K0031-343 [I,A]; A61K0031-381 [I,A];
A61K0031-385 [I,A]; A61K0031-44 [I,A]; A61K0031-505
[I,A]; A61P0003-00 [I,A]; A61P0025-00 [I,A];
A61P0035-00 [I,A]
OS MARPAT 142:212406
AB The invention discloses a method for the treatment of cachexia in a
subject in need of treatment. More specifically, the invention discloses
the use of retinoid compds. that act on retinoid X receptors (RXRs) for
the treatment of cachexia in a subject in need of treatment. The cachexia
is associated with a complication of a primary disease, condition or
disorder. Primary diseases, conditions and disorders include, but are not
limited to, cancer, AIDS, liver cirrhosis, diabetes mellitus, chronic
renal failure, chronic obstructive pulmonary disease, chronic cardiac
failure, immune system diseases (e.g., rheumatoid arthritis and systemic
lupus erythematosus), tuberculosis, cystic fibrosis, gastrointestinal
disorders (e.g., irritable bowel syndrome and inflammatory bowel disease),
Parkinson's disease, **anorexia nervosa**, dementia, major
depression, an aged condition, and sarcopenia.
ST cachexia treatment RXR retinoid ligand
IT Appetite
Body weight
Cachexia
Combination chemotherapy
Hypolipemic agents
(RXR retinoid ligands for cachexia treatment)
IT Hyperlipidemia
Retinoid X receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RXR retinoid ligands for cachexia treatment)
IT Retinoid X receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RXR α ; RXR retinoid ligands for cachexia treatment)
IT Retinoid X receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RXR α ; RXR retinoid ligands for cachexia treatment)
IT Retinoid X receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(RXR β ; RXR retinoid ligands for cachexia treatment)
IT Thyroid hormones
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(and analogs; RXR retinoid ligands for cachexia treatment)
IT Appetite
(**anorexia nervosa**, cachexia associated with; RXR
retinoid ligands for cachexia treatment)
IT Sequestering agents
(bile acid sequestrants; RXR retinoid ligands for cachexia treatment)
IT AIDS (disease)
Aging, animal
Biliary tract, neoplasm
Cirrhosis
Cystic fibrosis
Diabetes mellitus

Digestive tract, disease
 Digestive tract, neoplasm
 Esophagus, neoplasm
 Immune disease
 Leukemia
 Liver, neoplasm
 Lung, neoplasm
 Mammary gland, neoplasm
 Neoplasm
 Pancreas, neoplasm
 Parkinson's disease
 Tuberculosis
 (cachexia associated with; RXR retinoid ligands for cachexia treatment)
 IT Biological transport
 (cholesterol absorption inhibitors; RXR retinoid ligands for cachexia treatment)
 IT Lung, disease
 (chronic obstructive pulmonary disease, cachexia associated with; RXR retinoid ligands for cachexia treatment)
 IT Intestine, neoplasm
 (colorectal, cachexia associated with; RXR retinoid ligands for cachexia treatment)
 IT Mental and behavioral disorders
 (dementia, cachexia associated with; RXR retinoid ligands for cachexia treatment)
 IT Heart, disease
 Kidney, disease
 (failure, chronic, cachexia associated with; RXR retinoid ligands for cachexia treatment)
 IT Mental and behavioral disorders
 (major depression, cachexia associated with; RXR retinoid ligands for cachexia treatment)
 IT Lung, neoplasm
 (non-small-cell carcinoma; RXR retinoid ligands for cachexia treatment)
 IT Drug delivery systems
 (oral; RXR retinoid ligands for cachexia treatment)
 IT Carcinoma
 (pulmonary non-small-cell; RXR retinoid ligands for cachexia treatment)
 IT Carcinoma
 (pulmonary small-cell; RXR retinoid ligands for cachexia treatment)
 IT Muscle
 (sarcopenia, cachexia associated with; RXR retinoid ligands for cachexia treatment)
 IT Bile acids
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (sequestrants; RXR retinoid ligands for cachexia treatment)
 IT Lung, neoplasm
 (small-cell carcinoma; RXR retinoid ligands for cachexia treatment)
 IT Muscle, disease
 (wasting; RXR retinoid ligands for cachexia treatment)
 IT 59-67-6, Nicotinic acid, biological studies 59-67-6D, Nicotinic acid, derivs. 70-26-8, Ornithine 78-41-1, Triparanol 83-46-5, β -Sitosterol 90-26-6, α -Phenylbutyramide 313-05-3, Azacosterol 503-49-1, Meglutol 541-15-1, Carnitine 597-71-7, Pentaerythritol Tetraacetate 943-45-3D, Fibric acid, derivs. 959-10-4, Xenbucin 1239-29-8, Furazabol 1553-41-9, 5,8,11,14,17-Eicosapentaenoic acid 4091-75-2, Clomestronone 5108-94-1, Mytatrienediol 6964-20-1, Tiadenol 7236-47-7 9007-28-7, Chondroitin Sulfate 9011-18-1, Dextran Sulfate Sodium 9064-91-9, Detaxtran 11042-64-1, γ -Oryzanol 14417-88-0, Melinamide

16816-67-4, Pantethine 23288-49-5, Probucol 23602-78-0, Benfluorex
 23918-98-1, Eritadenine 54110-25-7, Pirozadil 57775-26-5, Sultosilic
 Acid 72420-38-3, Acifran 153559-49-0 186134-48-5 474654-29-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (RXR retinoid ligands for cachexia treatment)
 IT 57-88-5, Cholesterol, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (absorption inhibitors; RXR retinoid ligands for cachexia treatment)
 IT 9028-35-7, HMG-CoA reductase
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (inhibitors; RXR retinoid ligands for cachexia treatment)
 IT 1553-41-9, 5,8,11,14,17-Eicosapentaenoic acid
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (RXR retinoid ligands for cachexia treatment)
 RN 1553-41-9 HCAPLUS
 CN 5,8,11,14,17-Eicosapentaenoic acid (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

PAGE 1-A

$$\text{HO}_2\text{C}-(\text{CH}_2)_3-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}-\text{CH}_2-$$

PAGE 1-B

—CH=CH—Et

L46 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:941903 HCAPLUS
 DN 142:481325
 ED Entered STN: 08 Nov 2004
 TI Effect of fish oil on appetite and other symptoms in patients with
 advanced cancer and anorexia/cachexia: a double-blind, placebo,
 controlled study
 AU Bruera, Eduardo; Strasser, Florian; Palmer, J. Lynn; Willey, Jie; Calder,
 Kathryn; Amyotte, Gail; Baracos, Vickie
 CS Department of Palliative Care and Rehabilitation Medicine, The University
 of Texas M.D. Anderson Cancer Center, Houston, TX, USA
 SO Journal of Clinical Oncology (2003), 21(1), 129-134
 CODEN: JCONDN; ISSN: 0732-183X
 PB American Society of Clinical Oncology
 DT Journal
 LA English
 CC 18-5 (Animal Nutrition)
 Section cross-reference(s): 1
 AB The aim was to determine whether high doses of fish oil, administered over 2
 wk, improve symptoms in patients with advanced cancer and decreased weight
 and appetite. Sixty patients were randomly assigned to fish oil capsules
 or placebo. Appetite, tiredness, nausea, well-being, caloric intake,
 nutritional status, and function were prospectively assessed at days 1 and
 14. The baseline weight loss was 16±11 and 16.8 kg in the fish oil (n =
 30) and placebo (n = 30) group resp., whereas the baseline appetite (0 mm
 = best and 10 mm = worst) was 58±24 mm and 67±19 mm, resp. (P = not
 significant). The mean daily dose was 10±4 (fish oil group) and 9±3
 (placebo group) capsules, which provided 1.8 g of eicosapentaenoic

acid and 1.2 g of docosahexaenoic acid in the fish oil group. No significant differences in symptomatic or nutritional parameters were found ($P < .05$), and there was no correlation between changes in different variables between days 1 and 14 and the fish oil doses. Finally, the majority of the patients were not able to swallow more than 10 fish oil capsules per day, mainly because of burping and aftertaste. Fish oil did not significantly influence appetite, tiredness, nausea, well-being, caloric intake, nutritional status, or function after 2 wk compared with placebo in patients with advanced cancer and loss of both weight and appetite.

- ST fish oil appetite cancer **anorexia** cachexia
eicosapentaenoate docosahexaenoate
- IT Drugs
(appetite stimulants; effect of fish oil on appetite and other symptoms in cancer patients with **anorexia/cachexia**)
- IT **Cachexia**
(cancerous; effect of fish oil on appetite and other symptoms in cancer patients with **anorexia/cachexia**)
- IT **Anorexia**
Appetite
Body weight
Fatigue, biological
Human
Neoplasm
Nutrition, animal
(effect of fish oil on appetite and other symptoms in cancer patients with **anorexia/cachexia**)
- IT Fats and Glyceridic oils, biological studies
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fish; effect of fish oil on appetite and other symptoms in cancer patients with **anorexia/cachexia**)
- IT Appetite
(stimulants; effect of fish oil on appetite and other symptoms in cancer patients with **anorexia/cachexia**)
- IT 24880-45-3
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bon s,ste b v,rel effect of fish oil on appetite and other symptoms in cancer patients with **anorexia/cachexia**)
- IT 57-10-3, Hexadecanoic acid, biological studies 57-11-4, Octadecanoic acid, biological studies 60-33-3, 9,12-Octadecadienoic acid (9Z,12Z)-, biological studies 112-80-1, 9-Octadecenoic acid (9Z)-, biological studies 112-85-6, Docosanoic acid 373-49-9 506-17-2 506-30-9, Eicosanoic acid 506-32-1 544-63-8, Tetradecanoic acid, biological studies 5598-38-9 6217-54-5, DHA 10417-94-4 17046-59-2 20290-75-9 28874-58-0 28929-01-3 28933-89-3 31152-46-2
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of fish oil on appetite and other symptoms in cancer patients with **anorexia/cachexia**)
- IT 463-40-1
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(seffect of fish oil on appetite and other symptoms in cancer patients with **anorexia/cachexia**)
- RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Barber, M; Br J Cancer 1999, V81, P80 HCAPLUS
(2) Barber, M; Lipids 2001, V36, P347 HCAPLUS

- (3) Beck, S; Cancer Res 1991, V51, P6089 HCAPLUS
- (4) Bruera, E; Ann Oncol 1999, V10, P857 MEDLINE
- (5) Bruera, E; Cancer 1990, V66, P1279 MEDLINE
- (6) Bruera, E; Cancer 1990, V66, P1279 MEDLINE
- (7) Bruera, E; Cancer Prev Control 1998, V2, P74 MEDLINE
- (8) Bruera, E; Cancer Treat Rep 1985, V69, P751 MEDLINE
- (9) Bruera, E; Cancer Treat Rep 1986, V70, P981 MEDLINE
- (10) Bruera, E; Oxford Textbook of Palliative Medicine (ed 2) 1998, P548
- (11) Bruera, E; Support Care Cancer 2001, V9, P162 MEDLINE
- (12) Burns, C; Clin Cancer Res 1999, V5, P3942 HCAPLUS
- (13) Dunlop, R; Cachexia-Anorexia in Cancer Patients 1996, P76
- (14) Endres, S; N Engl J Med 1989, V320, P265 HCAPLUS
- (15) Fearon, K; Eur J Cancer 2001, V37, P27
- (16) Gagnon, B; Drugs 1998, V55, P675 HCAPLUS
- (17) Gogos, C; Cancer 1998, V82, P395 HCAPLUS
- (18) Hellerstein, M; J AIDS Hum Retrovirol 1996, V11, P258 HCAPLUS
- (19) Kaasa, T; Palliat Med 2000, V14, P509 MEDLINE
- (20) Maltoni, M; Ann Oncol 2001, V12, P289 MEDLINE
- (21) Meydani, S; J Clin Investig 1993, V92, P105 HCAPLUS
- (22) Nilsson, M; J Intern Med 2001, V250, P225 MEDLINE
- (23) Pereira, J; Cancer 1997, V79, P835 MEDLINE
- (24) Pratt, V; Lipids 2001, V36, P675 HCAPLUS
- (25) Simons, J; Am J Clin Nutr 1995, V61, P741 MEDLINE
- (26) Tisdale, M; Nutrition 1996, V12, PS31 MEDLINE
- (27) Tisdale, M; Nutrition 2000, V16, P1013 HCAPLUS
- (28) Tisdale, M; Science 2000, V289, P2293 HCAPLUS
- (29) Whitehouse, A; Cancer Res 2001, V61, P3604 HCAPLUS
- (30) Wigmore, S; Ann Surg 1997, V225, P103 MEDLINE
- (31) Wigmore, S; Br J Surg 2000, V87, P53 MEDLINE
- (32) Wigmore, S; Clin Sci (Colch) 1997, V92, P215 HCAPLUS
- (33) Wigmore, S; Nutr Cancer 2000, V36, P177 HCAPLUS
- (34) Wigmore, S; Nutrition 1996, V12, PS27 MEDLINE
- (35) Yaqoob, P; Eur J Clin Investig 2000, V30, P260 HCAPLUS

IT 10417-94-4


RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effect of fish oil on appetite and other symptoms in cancer patients with **anorexia**/cachexia)

RN 10417-94-4 HCAPLUS

CN 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L46 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:941700 HCAPLUS

DN 142:260641

ED Entered STN: 08 Nov 2004

TI An **eicosapentaenoic acid** supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a north central cancer treatment group and National Cancer Institute of Canada collaborative effort

AU Jatoi, Aminah; Rowland, Kendrith; Loprinzi, Charles L.; Sloan, Jeff A.;

Dakhil, Shaker R.; MacDonald, Neil; Gagnon, Bruno; Novotny, Paul J.;
Mailliard, James A.; Bushey, Teresita I. L.; Nair, Suresh; Christensen,
Brad

CS Mayo Clinic and Foundation, Rochester, USA

SO Journal of Clinical Oncology (2004), 22(12), 2469-2476

CODEN: JCONDN; ISSN: 0732-183X

PB American Society of Clinical Oncology

DT Journal

LA English

CC 18-5 (Animal Nutrition)

AB Purpose Studies suggest **eicosapentaenoic acid (EPA)**,
an omega-3 fatty acid, augments weight, appetite, and survival in
cancer-associated wasting. This study determined whether an EPA
supplement-administered alone or with megestrol acetate (MA) - was more
effective than MA. Patients and Methods Four hundred twenty-one
assessable patients with cancer-associated wasting were randomly assigned to
an EPA supplement 1.09 g administered bid plus placebo, MA liquid suspension
600 mg/d plus an isocaloric, isonitrogenous supplement administered twice
a day; or both. Eligible patients reported a 5-lb, 2-mo weight loss and/or
intake of less than 20 cal/kg/d. Results A smaller percentage taking the
EPA supplement gained $\geq 10\%$ of baseline weight compared with those
taking MA: 6% v 18%, resp. ($P = .004$). Combination therapy resulted in weight
gain of $\geq 10\%$ in 11% of patients ($P = .17$ across all arms). The
percentage of patients with appetite improvement (North Central Cancer
Treatment Group Questionnaire) was not statistically different: 63%, 69%,
and 66%, in EPA-, MA-, and combination-treated arms, resp. ($P = .69$). In
contrast, 4-wk Functional Assessment of **Anorexia/Cachexia**
Therapy scores suggested MA-containing arms experienced superior appetite
stimulation compared with the EPA arm, with scores of 40, 55, and 55 in
EPA-, MA-, and combination-treated arms, resp. ($P = .004$). Survival was
not significantly different among arms. Global quality of life was not
significantly different among groups. With the exception of increased
impotence in MA-treated patients, toxicity was comparable. Conclusion
This EPA supplement, either alone or in combination with MA, does not
improve weight or appetite better than MA alone.

ST **eicosapentaenoate** supplement megestrol acetate cancer wasting

IT **Anorexia**

Appetite

Body weight

Cachexia

Human

Neoplasm

(**eicosapentaenoic acid** supplement vs. megestrol
acetate vs. both for patients with cancer-associated wasting)

IT Fatty acids, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(polyunsatd., omega-3; **eicosapentaenoic acid**
supplement vs. megestrol acetate vs. both for patients with
cancer-associated wasting)

IT 595-33-5, Megestrol acetate 25378-27-2, **Eicosapentaenoic
acid**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(**eicosapentaenoic acid** supplement vs. megestrol
acetate vs. both for patients with cancer-associated wasting)

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

(1) Baracos, V; Am J Physiol 1995, V268, PE996 HCAPLUS

(2) Barber, M; Br J Cancer 1999, V81, P80 HCAPLUS

(3) Bridge, P; J Clin Epidemiol 1999, V52, P229 MEDLINE
 (4) Bruera, E; J Clin Oncol 2003, V21, P129 HCAPLUS
 (5) Cella, D; Qual Life Res 1995, V4, P221 MEDLINE
 (6) Emsley, R; Am J Psychiatry 2002, V159, P1596
 (7) Fearon, K; Gut 2003, V52, P1479 HCAPLUS
 (8) Geerling, B; Inflamm Bowel Dis 2000, V6, P77 MEDLINE
 (9) Gogos, C; Cancer 1998, V82, P395 HCAPLUS
 (10) Goldberg, R; J Clin Oncol 1995, V13, P2856 HCAPLUS
 (11) Hu, F; JAMA 2002, V287, P1815 HCAPLUS
 (12) Jatoi, A; J Clin Oncol 2002, V20, P567 HCAPLUS
 (13) Lachin, J; Control Clin Trials 2000, V21, P167 MEDLINE
 (14) Loprinzi, C; J Clin Oncol 1999, V17, P3299 HCAPLUS
 (15) Loprinzi, C; J Natl Cancer Inst 1990, V82, P1127 MEDLINE
 (16) Pocock, S; Clinical Trials:A Practical Approach 1983, P200
 (17) Rosenberg, I; N Engl J Med 2002, V346, P1102
 (18) Scott, N; Control Clin Trials 2002, V23, P662
 (19) Sloan, J; J Clin Oncol 1998, V16, P3662 MEDLINE
 (20) Sloan, J; J Clin Oncol 2001, V19, P3539 MEDLINE
 (21) Smith, H; Cancer Res 1999, V59, P5507 HCAPLUS
 (22) Valk, E; Int J Vitam Nutr Res 2000, V70, P31 HCAPLUS
 (23) Walsh, D; Support Care Cancer 2000, V8, P175 MEDLINE
 (24) Whitehouse, A; Cancer Res 2001, V61, P3604 HCAPLUS
 (25) Wigmore, S; Clin Sci 1997, V92, P215 HCAPLUS
 (26) Wigmore, S; Nutr Cancer 2000, V36, P177 HCAPLUS
 IT 25378-27-2, **Eicosapentaenoic acid**
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (eicosapentaenoic acid supplement vs. megestrol
 acetate vs. both for patients with cancer-associated wasting)
 RN 25378-27-2 HCAPLUS
 CN Eicosapentaenoic acid (8CI, 9CI) (CA INDEX NAME)
 CM 1
 CRN 506-30-9
 CMF C20 H40 O2

HO₂C-(CH₂)₁₈-Me

L46 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:811404 HCAPLUS
 DN 142:456951
 ED Entered STN: 06 Oct 2004
 TI Cancer-Related **Anorexia**/Cachexia Syndrome and Oxidative Stress:
 An Innovative Approach beyond Current Treatment
 AU Mantovani, Giovanni; Madeddu, Clelia; Maccio, Antonio; Gramignano, Giulia;
 Lusso, Maria Rita; Massa, Elena; Astara, Giorgio; Serpe, Roberto
 CS Department of Medical Oncology, University of Cagliari, Cagliari, Italy
 SO Cancer Epidemiology, Biomarkers & Prevention (2004), 13(10), 1651-1659
 CODEN: CEBPE4; ISSN: 1055-9965
 PB American Association for Cancer Research
 DT Journal
 LA English
 CC 1-12 (Pharmacology)
 AB Objective: Cancer-related **anorexia**/cachexia syndrome and
 oxidative stress play a key role in the progression and outcome of
 neoplastic disease. Patients and Methods: On the basis of our previously

published studies and clin. experience, we have developed an innovative approach consisting of diet with high polyphenol content (400 mg), p.o. pharmaconutritional support enriched with n - 3 fatty acids (**eicosapentaenoic acid** and **docosahexaenoic acid**) 2 cans (237 mL each) per day, medroxyprogesterone acetate 500 mg/d, antioxidant treatment with α -lipoic acid 300 mg/d plus carbocysteine lysine salt 2.7 g/d plus vitamin E 400 mg/d plus vitamin A 30,000 IU/d plus vitamin C 500 mg/d, and selective cyclooxygenase-2 inhibitor Celecoxib 200 mg/d. The treatment is administered for 16 wk. The following variables are evaluated: (a) clin. variables (stage and Eastern Cooperative Oncol. Group performance status); (b) nutritional variables (lean body mass, appetite, and resting energy expenditure); (c) laboratory variables (serum levels of proinflammatory cytokines, C-reactive protein, and leptin and blood levels of reactive oxygen species and antioxidant enzymes); and (d) quality of life variables (European Organization for Research and Treatment of Cancer QLQ-C30, EQ-5Dindex, and EQ-5DVAS). A phase II nonrandomized study has been designed to enroll 40 patients with advanced cancer at different sites with symptoms of cancer-related **anorexia/cachexia** syndrome and oxidative stress. Results: As of Jan. 2004, 28 patients have been enrolled: 25 patients were evaluable and 14 of them have completed the treatment (20 patients have completed 2 mo of treatment). As for clin. response, five patients improved, three patients remained unchanged, and six patients worsened. The Eastern Cooperative Oncol. Group performance status (grade) 1 remained unchanged. As for nutritional/functional variables, the lean body mass increased significantly at 2 and 4 mo. As for laboratory variables, reactive oxygen species decreased significantly and proinflammatory cytokines interleukin-6 and tumor necrosis factor- α decreased significantly. As for quality of life, it comprehensively improved after treatment. Conclusions: The treatment has been shown to be effective for clin. response, increase of lean body mass, decrease of reactive oxygen species and proinflammatory cytokines, and improvement of quality of life. The treatment has been shown to be safe with good compliance of patients. The study is in progress (14 further patients will be included).

- ST cancer **anorexia** cachexia syndrome oxidative stress antioxidant;
celecoxib fatty lipoic acid carbocysteine lysine polyphenol
medroxyprogesterone
- IT Antioxidants
(antioxidant therapy with α -lipoic acid + carbocysteine lysine salt + vitamins E + A + C was well tolerated, effective, raised LBM, reduced ROS, proinflammatory cytokines and improved life quality in advanced cancer patient with CACS/OS)
- IT Neoplasm
(polyphenol diet, n-3 fatty acids, progestagen, cyclooxygenase-2 inhibitor celecoxib and antioxidant therapy was well tolerated, effective for clin. response, raised LBM, reduced ROS, IL-6, TNF- in advanced cancer patient with CACS/OS)
- IT **Anorexia**
Cachexia
Human
Oxidative stress, biological
(polyphenol diet, n-3 fatty acids, progestagen, cyclooxygenase-2 inhibitor celecoxib and antioxidant therapy was well tolerated, effective for clin. response, raised LBM, reduced ROS, IL-6, TNF- α in advanced cancer patient with CACS/OS)
- IT Phenols, biological studies
RL: NPO (Natural product occurrence); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(polyphenols, nonpolymeric; diet with high polyphenol content was well tolerated, effective for clin. response and significantly increased

- LBM, appetite, decreased ROS, proinflammatory cytokines and improved quality of life in advanced cancer patient with CACS/OS)
- IT Fatty acids, biological studies
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (polyunsatd., omega-3; pharmaconutritional enriched with n-3 fatty acids (eicosapentaenoic, docosahexaenoic acid) was well tolerated, effective for clin. response and raised LBM, decreased ROS, proinflammatory cytokines in advanced cancer patient with CACS/OS)
- IT Progestogens
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (progestagen medroxyprogesterone acetate was well tolerated, effective for clin. response and significantly raised LBM, appetite, reduced ROS, proinflammatory cytokines and improved quality of life in advanced cancer patient with CACS/OS)
- IT Cytokines
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (proinflammatory; serum levels of proinflammatory cytokines, C-reactive protein, and leptin and blood levels of reactive oxygen species and antioxidant enzymes were evaluated)
- IT C-reactive protein
 Interleukin 6
 Reactive oxygen species
 Tumor necrosis factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (serum levels of proinflammatory cytokines, C-reactive protein, and leptin and blood levels of reactive oxygen species and antioxidant enzymes were evaluated)
- IT Combination chemotherapy
 (α-lipoic acid, carbocysteine lysine salt, vitamin E, A, C combination was well tolerated, effective for clin. response and significantly increased LBM, decreased ROS, proinflammatory cytokines in advanced cancer patient with CACS/OS)
- IT 11103-57-4, Vitamin A
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (α-lipoic acid, carbocysteine lysine salt, vitamin E, A, C combination was well tolerated, effective for clin. response and significantly increased LBM, decreased ROS, proinflammatory cytokines in advanced cancer patient with CACS/OS)
- IT 329900-75-6, Cyclooxygenase-2
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cyclooxygenase-2 inhibitor celecoxib was well tolerated, effective for clin. response and significantly increased LBM, appetite, reduced ROS, proinflammatory cytokines and improved quality of life in advanced cancer patient with CACS/OS)
- IT 169590-42-5, Celebrex
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (cyclooxygenase-2 inhibitor celecoxib was well tolerated, effective for clin. response and significantly increased LBM, appetite, reduced ROS, proinflammatory cytokines and improved quality of life in advanced cancer patient with CACS/OS)
- IT 71-58-9, Provera
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (medroxyprogesterone acetate therapy was well tolerated, effective for clin. response and significantly increased LBM, appetite, reduced ROS, proinflammatory cytokines and improved quality of life in advanced

- cancer patient with CACS/OS)
- IT 6217-54-5, Docosahexaenoic acid
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaconutritional enriched with n-3 fatty acids (docosahexaenoic acid) was well tolerated, effective for clin. response, increased LBM, reduced ROS, proinflammatory cytokines and improved life in advanced cancer patient with CACS/OS)
- IT 10417-94-4, Eicosapentaenoic acid
 851541-58-7, ProSure
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaconutritional enriched with n-3 fatty acids (eicosapentaenoic acid) was well tolerated, effective for clin. response, increased LBM, reduced ROS, proinflammatory cytokines and improved life in advanced cancer patient with CACS/OS)
- IT 7782-44-7D, Oxygen, reactive species 169494-85-3, Leptin
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (serum levels of proinflammatory cytokines, C-reactive protein, and leptin and blood levels of reactive oxygen species and antioxidant enzymes were evaluated)
- IT 50-81-7, Vitamin C, biological studies 1200-22-2, Tiobec 1406-18-4, Vitamin E 49673-81-6, Fluifort
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (α -lipoic acid, carbocysteine lysine salt, vitamin E, A, C combination was well tolerated, effective for clin. response and significantly increased LBM, decreased ROS, proinflammatory cytokines in advanced cancer patient with CACS/OS)


RE.CNT 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Ahima, R; Nature 1996, V382, P250 HCAPLUS
- (2) Alberti, A; Res Chem Intermed 2000, V26, P253 HCAPLUS
- (3) Aoe, T; J Exp Med 1995, V181, P1881 HCAPLUS
- (4) Argiles, J; Med Res Rev 2001, V21, P83 HCAPLUS
- (5) Asakawa, A; Gastroenterology 2001, V120, P337 HCAPLUS
- (6) Barber, M; Br J Cancer 1999, V81, P80 HCAPLUS
- (7) Barber, M; Clin Sci (Lond) 2000, V98, P389 HCAPLUS
- (8) Barber, M; J Nutr 1999, V129, P1120 HCAPLUS
- (9) Bingisser, R; J Immunol 1998, V160, P5729 HCAPLUS
- (10) Brennan, M; Cancer Res 1977, V37, P2359 HCAPLUS
- (11) Bruera, E; BMJ 1997, V315, P1219 MEDLINE
- (12) Bruera, E; Oncology 1992, V49, P35
- (13) Buck, M; EMBO J 1996, V15, P1753 HCAPLUS
- (14) Busbridge, J; Proc Nutr Soc 1989, V38, P48A
- (15) Chandel, N; Proc Natl Acad Sci U S A 1998, V95, P11715 HCAPLUS
- (16) Droge, W; Biol Chem Hoppe-Seyler 1988, V369, P143 MEDLINE
- (17) Droge, W; J Cancer Clin Oncol 1988, V114, P124 MEDLINE
- (18) Eck, H; J Cancer Clin Oncol 1989, V115, P571 MEDLINE
- (19) Eck, H; Lancet 1991, V338, P346 MEDLINE
- (20) Fearon, K; Gut 2003, V52, P1479 HCAPLUS
- (21) Gelin, J; Cancer Res 1991, V51, P415 HCAPLUS
- (22) Giulivi, C; Biochem J 1998, V332, P673 HCAPLUS
- (23) Grob, A; AIDS Res Hum Retroviruses 1996, V12, P1639
- (24) Ha, H; Proc Natl Acad Sci U S A 1998, V95, P11140 HCAPLUS
- (25) Hack, V; FASEB J 1996, V10, P1219 HCAPLUS
- (26) Hack, V; J Mol Med 1996, V74, P337 HCAPLUS
- (27) Heber, D; Cancer 1986, V58, P1867 MEDLINE
- (28) Higdon, J; Crit Rev Food Sci Nutr 2003, V43, P89 HCAPLUS
- (29) Igarashi, K; Cancer Res 1995, V55, P2615 HCAPLUS

- (30) Inui, A; Cancer Res 1999, V59, P4493 HCAPLUS
 - (31) Inui, A; Nat Rev Neurosci 2001, V2, P551 HCAPLUS
 - (32) Inui, A; Trends Neurosci 1999, V22, P62 HCAPLUS
 - (33) Jain, A; Proc Natl Acad Sci U S A 1991, V88, P1913 HCAPLUS
 - (34) Kono, K; Eur J Immunol 1996, V26, P1308 HCAPLUS
 - (35) Kotler, D; Ann Intern Med 2000, V133, P622 HCAPLUS
 - (36) Kroemer, G; FASEB J 1995, V9, P1277 HCAPLUS
 - (37) Kurose, I; Cancer Res 1993, V53, P2676 HCAPLUS
 - (38) Lechan, R; Endocrinology 2001, V142, P3288 HCAPLUS
 - (39) Loprinzi, C; J Clin Oncol 1999, V17, P3299 HCAPLUS
 - (40) Loschen, G; FEBS Lett 1974, V42, P68 MEDLINE
 - (41) Macdonald, N; Nutrition 2000, V16, P1007
 - (42) Madsen, K; Am J Physiol 1996, V270, PG789 HCAPLUS
 - (43) Malmberg, K; Clin Cancer Res 2002, V8, P1772 HCAPLUS
 - (44) Mantovani, G; Drugs 2001, V61, P499 HCAPLUS
 - (45) Mantovani, G; Eur J Cancer 1997, V33, P602 HCAPLUS
 - (46) Mantovani, G; Free Radic Res 2003, V37, P213 HCAPLUS
 - (47) Mantovani, G; Int J Cancer 2000, V86, P842 HCAPLUS
 - (48) Mantovani, G; Int J Cancer 2002, V98, P84 HCAPLUS
 - (49) Mantovani, G; J Mol Med 2000, V7, P554
 - (50) Mantovani, G; J Mol Med 2001, V79, P406 HCAPLUS
 - (51) Mantovani, G; Semin Oncol 1998, V25, P45 HCAPLUS
 - (52) Marks, D; Cancer Res 2001, V61, P1432 HCAPLUS
 - (53) McLaughlin, C; Physiol Behav 1992, V52, P1155 HCAPLUS
 - (54) Meister, A; Biochim Biophys Acta 1995, V1271, P35 HCAPLUS
 - (55) Moldawer, L; Am J Physiol 1987, V253, PR922 HCAPLUS
 - (56) Nelson, K; Cancer Bull 1991, V43, P403
 - (57) Nelson, K; Semin Oncol 2000, V27, P64 HCAPLUS
 - (58) Nitenberg, G; Crit Rev Oncol Hematol 2000, V34, P137 MEDLINE
 - (59) Oken, M; Am J Clin Oncol 1982, V5, P649 MEDLINE
 - (60) Otjuji, M; Proc Natl Acad Sci U S A 1996, V93, P13119
 - (61) Plaitakis, A; Ann Neurol 1987, V22, P575 HCAPLUS
 - (62) Richter, C; Chem Biol Interact 1991, V77, P1 HCAPLUS
 - (63) Roth, E; Clin Nutr 1982, V1, P25
 - (64) Sabitha, K; Oral Oncol 1999, V35, P273 MEDLINE
 - (65) Schwartz, M; Am J Physiol 1995, V269, P949
 - (66) Schwartz, M; N Engl J Med 1997, V336, P1802 HCAPLUS
 - (67) Schweizer, M; Biochem Biophys Res Commun 1994, V204, P169 HCAPLUS
 - (68) Shaw, J; Surgery (St Louis) 1987, V101, P181 MEDLINE
 - (69) Stein, K; Cancer Pract 1998, V6, P143 MEDLINE
 - (70) Strassmann, G; J Clin Invest 1992, V89, P1681 HCAPLUS
 - (71) Striebel, J; Infusionstherapie 1986, V13, P92 MEDLINE
 - (72) Szabo, C; Br J Pharmacol 1994, V113, P757 HCAPLUS
 - (73) Tassani, V; Biochem Biophys Res Commun 1995, V207, P661 HCAPLUS
 - (74) Tatoyan, A; J Biol Chem 1998, V273, P11044 HCAPLUS
 - (75) Tayek, J; J Am Coll Nutr 1992, V11, P445 MEDLINE
 - (76) Therasse, P; J Natl Cancer Inst 2000, V92, P205 MEDLINE
 - (77) Tisdale, M; Front Biosci 2001, V6, PD164 HCAPLUS
 - (78) Virag, L; J Immunol 1998, V161, P3753 HCAPLUS
 - (79) Weijl, N; Cancer Treat Rev 1997, V23, P209 HCAPLUS
 - (80) Wilmore, D; Surg Clin North Am 1978, V58, P1173 HCAPLUS
- IT 10417-94-4, **Eicosapentaenoic acid**
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (pharmacological enriched with n-3 fatty acids (
eicosapentaenoic acid) was well tolerated, effective
 for clin. response, increased LBM, reduced ROS, proinflammatory
 cytokines and improved life in advanced cancer patient with CACS/OS)
- RN 10417-94-4 HCAPLUS
- CN 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (9CI) (CA INDEX

NAME)


Double bond geometry as shown.



L46 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:644904 HCAPLUS
 DN 141:349352
 ED Entered STN: 11 Aug 2004
 TI A pilot open case series of Ethyl-EPA supplementation in the treatment of
anorexia nervosa
 AU **Ayton, Agnes K.; Azaz, Amer; Horrobin, David F.**
 CS Hull and East Riding Community NHS Trust, ST19 9QT, UK
 SO Prostaglandins, Leukotrienes and Essential Fatty Acids (2004), 71(4),
 205-209
 CODEN: PLEAEU; ISSN: 0952-3278
 PB Elsevier B.V.
 DT Journal
 LA English
 CC 18-5 (Animal Nutrition)
 AB **Anorexia nervosa** (AN) carries the highest risk of
 morbidity and mortality amongst psychiatric disorders. The efficacy of
 current treatment approaches is limited. Despite the fat-phobic nature of
 the disease, poly-unsatd. fatty acids (PUFAs) have not received much
 research attention. Patients who consume western diet, which is rich in
 n-6 PUFAs and trans-fatty acids, are likely to develop severe n-3 PUFA
 deficiency during self-induced starvation. Re-feeding programs do not
 take into consideration n-3 EFA intake, possibly leading to further n-3
 PUFA deficiency during weight restoration, and this might contribute to the
 maintenance of the disorder. To test this hypothesis, we carried out a
 systematic case series of E-EPA supplementation in the treatment of AN.
 Seven young patients received 1 g/day E-EPA in addition to standard treatment,
 and were followed up for 3 mo. Three of them recovered and four improved.
 Randomized controlled trials are warranted to examine the effectiveness of
 E-EPA in AN further.
 ST **eicosapentaenoate anorexia nervosa**
 IT Appetite
 (anorexia nervosa; fatty acid supplementation and
 anorexia nervosa)
 IT 10417-94-4, **Eicosapentaenoic acid**
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (fatty acid supplementation and **anorexia nervosa**)
 RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Ben Tovim, D; Lancet 2001, V357(9264), P1254 MEDLINE
 (2) Bjerve, K; J Parenter Enter Nutr 1988, V12(5), P521 MEDLINE
 (3) Connor, W; Am J Clin Nutr 2000, V71(1 Suppl), P171S MEDLINE
 (4) Emsley, R; Am J Psychiatry 2002, V159(9), P1596
 (5) Fenton, W; Am J Psychiatry 2001, V158(12), P2071 MEDLINE
 (6) Heird, W; Pediatr Clin North Am 2001, V48(1), P173 MEDLINE
 (7) Holman, R; J Nutr 1995, V125(4), P901 HCAPLUS
 (8) Langan, S; Am J Clin Nutr 1985, V41(5), P1054 HCAPLUS
 (9) Nemets, B; Am J Psychiatry 2002, V159(3), P477
 (10) Peet, M; Arch Gen Psychiatry 2002, V59(10), P913 HCAPLUS

(11) Peet, M; Arch Gen Psychiatry 2002, V59(10), P913 HCAPLUS
 (12) Puri, B; Int J Clin Pract 2001, V55(8), P560 MEDLINE
 (13) Simopoulos, A; Biomed Pharmacother 2002, V56, P365 HCAPLUS
 (14) Steinhausen, H; Am J Psychiatry 2002, V159(8), P1284
 (15) Tisdale, M; Nutrition 1996, V12(1 Suppl), P531 MEDLINE
 (16) von Meyenfeldt, M; Proc Am Soc Clin Oncol 2002, V21, P385A
 IT 10417-94-4, **Eicosapentaenoic acid**
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (fatty acid supplementation and **anorexia nervosa**)
 RN 10417-94-4 HCAPLUS
 CN 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L46 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:317047 HCAPLUS
 DN 141:105641
 ED Entered STN: 19 Apr 2004
 TI Dietary polyunsaturated fatty acids and **anorexia nervosa**
 : Is there a link?
 AU **Ayton, Agnes K.**
 CS Consultant Child and Adolescent Psychiatrist, Eating Disorders Unit,
 Huntercombe Stafford Hospital, Staffordshire, ST19 9QT, UK
 SO Nutritional Neuroscience (2004), 7(1), 1-12
 CODEN: NNINFE; ISSN: 1028-415X
 PB Taylor & Francis Ltd.
 DT Journal; General Review
 LA English
 CC 18-0 (Animal Nutrition)
 Section cross-reference(s): 14
 AB A review. There has been little research examining the link between dietary fat intake and the symptoms and consequences of **anorexia nervosa**. In this selective literature review, the potential significance of poly-unsatd. fatty acids is discussed. It is hypothesised that dietary restriction causes essential fatty acid deficiencies and poly-unsatd. fatty acid abnormalities, which might contribute to the phys. and mental symptoms and the maintenance of the disorder. The examination of epidemiol., symptoms, co-morbidity, and consequences suggest that poly-unsatd. fatty acid and phospholipid abnormalities are significant in **anorexia nervosa**. This will be an important area for future research, and may lead to the development of new interventions.
 ST review diet polyunsatd fatty acid **anorexia nervosa**
 IT Appetite
 (anorexia nervosa; dietary polyunsatd. fatty acids and anorexia nervosa)
 IT Diet
 Human
 (dietary polyunsatd. fatty acids and **anorexia nervosa**)
 IT Fatty acids, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (polyunsatd., omega-3; dietary polyunsatd. fatty acids and

anorexia nervosa)

IT Fatty acids, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (polyunsatd.; dietary polyunsatd. fatty acids and anorexia
 nervosa)

RE.CNT 144 THERE ARE 144 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Allen, K; Experimental Biology and Medicine 2001, V226, P498 HCAPLUS
- (2) Audi, L; Molecular Psychiatry 1998, V3, P544 HCAPLUS
- (3) Bakan, R; International Journal of Eating Disorders 1993, V13, P229 MEDLINE
- (4) Barber, M; Journal of Nutrition 1999, V129, P1120 HCAPLUS
- (5) Birch, E; American Journal of Clinical Nutrition 2002, V75, P570 HCAPLUS
- (6) Birmingham, C; International Journal of Eating Disorders 1994, V15, P251 MEDLINE
- (7) Bjerve, K; Advances in Prostaglandin, Thromboxane, and Leukotriene Research 1987, V17B, P862 MEDLINE
- (8) Bjerve, K; American Journal of Clinical Nutrition 1989, V49, P290 HCAPLUS
- (9) Bjerve, K; Journal of Internal Medicine 1989, V225(Suppl), P171
- (10) Bjerve, K; Jpen: Journal of Parenteral and Enteral Nutrition 1988, V12, P521 MEDLINE
- (11) Boland, B; International Journal of Eating Disorders 2001, V30, P299 MEDLINE
- (12) Brinch, M; Acta Psychiatrica Scandinavica 1988, V77, P611 MEDLINE
- (13) Brinch, M; republished from Acta Psychiatr Scand 1988, V77(1), P98
- (14) Bulik, C; Journal of Clinical Psychiatry 1999, V60, P130 MEDLINE
- (15) Burdge, G; British Journal of Nutrition 2002, V88, P411 HCAPLUS
- (16) Buydens-Branch; Drug and Alcohol Dependence, In Press, Corrected Proof 2003
- (17) Calder, P; British Journal of Nutrition 2002, V87(Suppl 1), PS31
- (18) Calder, P; Lipids 2001, V36, P1007 HCAPLUS
- (19) Calder, P; Proceedings of the Nutrition Society 2002, V61, P345 HCAPLUS
- (20) Case, T; International Journal of Eating Disorders 1999, V25, P187 MEDLINE
- (21) Casper, R; Depression and Anxiety 1998, V8(Suppl 1), P96
- (22) Cnattingius, S; Archives of General Psychiatry 1999, V56, P634 MEDLINE
- (23) Conti, J; Journal of Psychosomatic Research 1998, V44, P465 MEDLINE
- (24) Crow, S; International Journal of Eating Disorders 1999, V26, P97 MEDLINE
- (25) Cunnane, S; Canadian Journal of Physiology and Pharmacology 1995, V73, P1246 HCAPLUS
- (26) Donohoe, T; Life Sciences 1984, V34, P203 HCAPLUS
- (27) Drewnowski, A; Appetite 1988, V10, P119 MEDLINE
- (28) Dubois, A; Gastroenterology 1979, V77, P319 MEDLINE
- (29) Duman, R; Journal of the American Academy of Child and Adolescent Psychiatry 2002, V41, P745
- (30) Durrington, P; Heart (British Cardiac Society) 2001, V85, P544 MEDLINE
- (31) Eder, K; Biological Trace Element Research 1996, V54, P173 HCAPLUS
- (32) Fearon, K; European Journal of Cancer 2001, V37, P90
- (33) Fenton, W; American Journal of Psychiatry 2001, V158, P2071 MEDLINE
- (34) Fenton, W; Biological Psychiatry 2000, V47, P8 HCAPLUS
- (35) Fichter, M; European Archives of Psychiatry and Neurological Sciences 1988, V237, P200 MEDLINE
- (36) Foley, D; American Journal of Medical Genetics 2001, V105, P426 MEDLINE
- (37) Franko, D; American Journal of Psychiatry 2001, V158, P1461 MEDLINE
- (38) Frederich, R; Journal of Laboratory and Clinical Medicine 2002, V139, P72 HCAPLUS
- (39) Geiser, F; Psychosomatic Medicine 2001, V63, P631 MEDLINE
- (40) Gerster, H; International Journal for Vitamin and Nutrition Research 1998, V68, P159 HCAPLUS
- (41) Grinspoon, S; Annals of Internal Medicine 2000, V133, P790 MEDLINE
- (42) Grinspoon, S; Journal of Clinical Endocrinology and Metabolism 1996, V81, P3861 HCAPLUS

- (43) Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico; Lancet 1999, V354, P447
- (44) Haluzik, M; Physiological Research 1999, V48, P197 MEDLINE
- (45) Hambidge, M; Journal of Nutrition 2000, V130, P1344S HCAPLUS
- (46) Harper, C; Archives of Internal Medicine 2001, V161, P2185 HCAPLUS
- (47) Hartman, D; International Journal of Eating Disorders 2000, V28, P107 MEDLINE
- (48) Hergenroeder, A; Journal of Pediatrics 1995, V126, P683 MEDLINE
- (49) Herzog, D; International Journal of Eating Disorders 2000, V28, P20 MEDLINE
- (50) Herzog, D; Psychiatric Clinics of North America 1996, V19, P843 MEDLINE
- (51) Hibbeln, J; Biological Psychiatry 1998, V44, P243 HCAPLUS
- (52) Hibbeln, J; World Review of Nutrition and Dietetics 1997, V82, P175 MEDLINE
- (53) Hibbeln, J; World Review of Nutrition and Dietetics 2001, V88, P41 MEDLINE
- (54) Holman, R; Journal of Nutrition 1995, V125, P901 HCAPLUS
- (55) Hornstra, G; American Journal of Clinical Nutrition 2000, V71, P1262S HCAPLUS
- (56) Horrobin, D; Medical Hypotheses 1980, V6, P277 MEDLINE
- (57) Horrobin, D; Prostaglandins Leukotrienes and Essential Fatty Acids 1999, V60, P217 HCAPLUS
- (58) Horrobin, D; Schizophrenia Research 1994, V13, P195 MEDLINE
- (59) Hsu, L; Psychological Medicine 1997, V27, P509 MEDLINE
- (60) Janeckova, R; Physiological Research 2001, V50, P443 HCAPLUS
- (61) Joy, C; Cochrane Database of Systematic Reviews 2003, PCD001257 MEDLINE
- (62) Joy, C; update of Cochrane Database Syst Rev 2003, 2, PCD001257 MEDLINE
- (63) Kang, J; American Journal of Clinical Nutrition 2000, V71, P202S HCAPLUS
- (64) Karmali, R; Nutrition 1996, V12, PS2 MEDLINE
- (65) Kato, T; Progress in Neuro-Psychopharmacology and Biological Psychiatry 1997, V21, P719 HCAPLUS
- (66) Kaye, W; Biological Psychiatry 2001, V49, P644 HCAPLUS
- (67) Keel, P; Archives of General Psychiatry 2003, V60, P179
- (68) Kelley, D; Nutrition 2001, V17, P669 HCAPLUS
- (69) Klump, K; Psychiatric Clinics of North America 2001, V24, P215 MEDLINE
- (70) Kopp, W; Molecular Psychiatry 1997, V2, P335 MEDLINE
- (71) Kris-Etherton, P; American Journal of Clinical Nutrition 2000, V71, P179S HCAPLUS
- (72) Kruger, M; Aging (Milano) 1998, V10, P385 HCAPLUS
- (73) Kruger, M; Progress in Lipid Research 1997, V36, P131 HCAPLUS
- (74) Langan, S; American Journal of Clinical Nutrition 1985, V41, P1054 HCAPLUS
- (75) Lask, B; Journal of Clinical Psychiatry 1993, V54, P63 MEDLINE
- (76) Lear, S; International Journal of Eating Disorders 1999, V26, P283 MEDLINE
- (77) Li, D; American Journal of Clinical Nutrition 1999, V69, P872 HCAPLUS
- (78) Lucas, A; American Journal of Psychiatry 1991, V148, P917 MEDLINE
- (79) Maes, M; Biological Psychiatry 2000, V47, P910 HCAPLUS
- (80) Mantzoros, C; Annals of the New York Academy of Sciences 2000, V900, P174 HCAPLUS
- (81) Mehler, P; International Journal of Eating Disorders 1998, V24, P217 MEDLINE
- (82) Mezzano, D; Thrombosis Research 2000, V100, P153 HCAPLUS
- (83) Munoz, M; European Journal of Endocrinology 2002, V146, P45 HCAPLUS
- (84) Nakamura, K; International Journal of Eating Disorders 2000, V28, P173 MEDLINE
- (85) Nakamura, M; Lipids 2001, V36, P961 HCAPLUS
- (86) Nemets, B; American Journal of Psychiatry 2002, V159, P477
- (87) Neumark-Sztainer, D; Archives of Pediatrics and Adolescent Medicine 1997, V151, P833 MEDLINE
- (88) Nielsen, S; Acta Psychiatrica Scandinavica 1990, V81, P507 MEDLINE
- (89) Nielsen, S; Journal of Psychosomatic Research 1998, V44, P413 MEDLINE
- (90) Olsen, S; British Journal of Obstetrics and Gynaecology 2000, V107, P382

HCAPLUS

- (91) O'Connor, M; Medical Journal of Australia 1987, V147, P540 MEDLINE
- (92) Peet, M; Archives of General Psychiatry 2002, V59, P913 HCAPLUS
- (93) Peet, M; Journal of Psychiatric Research 2002, V36, P7
- (94) Peet, M; Phospholipid spectrum disorder in psychiatry 1999
- (95) Perry, C; Journal of Adolescent Health 2001, V29, P406 MEDLINE
- (96) Puri, B; Archives of General Psychiatry 1998, V55, P188 MEDLINE
- (97) Puri, B; Archives of General Psychiatry 2002, V59, P91
- (98) Puri, B; International Journal of Clinical Practice 2000, V54, P57 HCAPLUS
- (99) Puri, B; International Journal of Clinical Practice 2001, V55, P560
MEDLINE
- (100) Rapoport, S; Journal of Molecular Neuroscience 2001, V16, P243 HCAPLUS
- (101) Requirand, P; Clinical Nutrition 2000, V19, P271 HCAPLUS
- (102) Reseland, J; Journal of Lipid Research 2001, V42, P743 HCAPLUS
- (103) Rink, L; Proceedings of the Nutrition Society 2000, V59, P541 HCAPLUS
- (104) Robertson, M; American Journal of Clinical Nutrition 2002, V76, P232
HCAPLUS
- (105) Robinson, E; Journal of Adolescent Health 2000, V26, P343 MEDLINE
- (106) Rooney, B; International Journal of Eating Disorders 1995, V18, P299
MEDLINE
- (107) Roser, W; International Journal of Eating Disorders 1999, V26, P119
MEDLINE
- (108) Russell, G; Psychological Medicine 1998, V28, P93 MEDLINE
- (109) Safai-Kutti, S; Acta Psychiatrica Scandinavica, Supplementum 1990, V361,
P14 MEDLINE
- (110) Sakaguchi, K; Prostaglandins Leukotrienes and Essential Fatty Acids 1994,
V50, P81 HCAPLUS
- (111) Sanchez-Muniz, F; European Journal of Clinical Nutrition 1991, V45, P33
MEDLINE
- (112) Sanders, T; American Journal of Clinical Nutrition 1999, V70, P555S
HCAPLUS
- (113) Schloss, I; South African Medical Journal 1997, V87, P152 MEDLINE
- (114) Schmidt, U; Psychological Medicine 1997, V27, P523 MEDLINE
- (115) Shay, N; Journal of Nutrition 2000, V130, P1493S HCAPLUS
- (116) Simopoulos, A; Biomedicine and Pharmacotherapy 2002, V56, P365 HCAPLUS
- (117) Simopoulos, A; Journal of Nutrition 1989, V119, P521 MEDLINE
- (118) Simopoulos, A; Journal of the American College of Nutrition 2002, V21,
P495 HCAPLUS
- (119) Sokol, M; Journal of Child and Adolescent Psychopharmacology 2000, V10,
P133 MEDLINE
- (120) Steinhausen, H; American Journal of Psychiatry 2002, V159, P1284
- (121) Stoll, A; Archives of General Psychiatry 1999, V56, P407 HCAPLUS
- (122) Strober, M; Journal of Child and Adolescent Psychopharmacology 1999, V9,
P195 MEDLINE
- (123) Strumia, R; Dermatology 2001, V203, P314 MEDLINE
- (124) Sugano, M; Current Opinion in Lipidology 1996, V7, P38 HCAPLUS
- (125) Takeda, A; Biometals 2001, V14, P343 HCAPLUS
- (126) Tanskanen, A; Psychiatric Services 2001, V52, P529 MEDLINE
- (127) Terano, T; World Review of Nutrition and Dietetics 2001, V88, P141
HCAPLUS
- (128) Tisdale, M; Nutrition 1996, V12, PS31 MEDLINE
- (129) Treasure, J; Hospital Medicine (London) 1999, V60, P477 MEDLINE
- (130) Treasure, J; Psychiatric Clinics of North America 2001, V24, P359 MEDLINE
- (131) Tsai, G; Eating & Weight Disorders: EWD 2000, V5, P183 MEDLINE
- (132) Tsuge, H; Journal of Nutrition 2000, V130, P333S HCAPLUS
- (133) Wade, T; American Journal of Psychiatry 2000, V157, P469 MEDLINE
- (134) Ward, G; Lipids 1996, V31, P71 HCAPLUS
- (135) Watkins, B; Experimental Biology and Medicine 2001, V226, P485 HCAPLUS
- (136) Watkins, B; Journal of Nutrition 2000, V130, P2274 HCAPLUS
- (137) Wauben, I; Journal of Nutrition 1999, V129, P1773 HCAPLUS

- (138) Waugh, E; International Journal of Eating Disorders 1999, V25, P123
MEDLINE
- (139) Whitehouse, A; Biochemical and Biophysical Research Communications 2001,
V285, P598 HCAPLUS
- (140) Wigmore, S; Nutrition and Cancer 2000, V36, P177 HCAPLUS
- (141) Winnicki, M; Circulation 2002, V106, P289 HCAPLUS
- (142) Zanarini, M; American Journal of Psychiatry 2003, V160, P167
- (143) Ziboh, V; American Journal of Clinical Nutrition 2000, V71, P361S HCAPLUS
- (144) Zipfel, S; Journal of Clinical Endocrinology and Metabolism 2001, V86,
P5227 HCAPLUS

L46 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2003:821113 HCAPLUS

DN 139:393945

ED Entered STN: 20 Oct 2003

TI Pathogenesis of cancer cachexia

AU Tisdale, Michael J.

CS Cancer Biochemistry at the Pharmaceutical Sciences Research Institute,
Aston University, Birmingham, UK

SO Journal of Supportive Oncology (2003), 1(3), 159-168
CODEN: JSOBY; ISSN: 1544-6794

PB BioLink Communications, Inc.

DT Journal; General Review

LA English

CC 14-0 (Mammalian Pathological Biochemistry)

Section cross-reference(s): 1

AB A review. Cachexia is a progressive wasting syndrome characterized by extensive loss of adipose tissue and skeletal muscle. It occurs in about half of all cancer patients. While **anorexia** also may be present, the energy deficit alone does not explain the pathogenesis of cachexia. The presence of an acute phase response (APR) has been linked to accelerated weight loss and a shortened survival time. The APR is thought to be initiated by cytokines such as interleukin (IL)-6 and IL-8, production of which is induced by a tumor factor, proteolysis inducing factor (PIF). Cachectic cancer patients also show an increased expression of uncoupling protein-3 in muscle, which may act as an energy sink, increasing energy expenditure. Loss of adipose tissue appears to be due to an increase in degradation of triglycerides, rather than a decrease in synthesis. One candidate for this effect is a tumor lipid mobilizing factor which stimulates lipolysis directly through a cAMP-mediated process via interaction with a β 3-adrenergic receptor. Loss of skeletal muscle arises from both a depression in protein synthesis and an increase in protein degradation. The major proteolytic pathway involved in intracellular protein breakdown in cachectic muscle is the ATP-ubiquitin-dependent proteolytic pathway. Both PIF and tumor necrosis factor- α , but not other cytokines, can induce expression of the key regulatory components of this pathway. **Eicosapentaenoic acid**, found in oily fish, effectively attenuates protein degradation in cachectic muscle by inhibiting the increased proteasome expression and can stabilize body weight in cachectic cancer patients.

ST review acute phase response interleukin TNF cytokine cancer cachexia;
ubiquitin proteasome proteolysis energy metab cancer cachexia review;
glyceride degrdn lipolysis **eicosapentaenoate** cancer cachexia
review

IT Uncoupling protein

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(3; role of acute-phase response, cytokines, hypermetabolism, energy
expenditure, and ubiquitin proteasome proteolytic pathway in
pathogenesis of cancer cachexia)

IT Proteins

- RL: BSU (Biological study, unclassified); BIOL (Biological study)
(PIF (proteolysis-inducing factor); role of acute-phase response, cytokines, hypermetabolism, energy expenditure, and ubiquitin proteasome proteolytic pathway in pathogenesis of cancer cachexia)
- IT **Cachexia**
(cancerous; role of acute-phase response, cytokines, hypermetabolism, energy expenditure, and ubiquitin proteasome proteolytic pathway in pathogenesis of cancer cachexia)
- IT Glycerides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(degradation of; role of acute-phase response, cytokines, hypermetabolism, energy expenditure, and ubiquitin proteasome proteolytic pathway in pathogenesis of cancer cachexia)
- IT Acute-phase response
Energy metabolism, animal
Human
Translation, genetic
(role of acute-phase response, cytokines, hypermetabolism, energy expenditure, and ubiquitin proteasome proteolytic pathway in pathogenesis of cancer cachexia)
- IT Interleukin 6
Interleukin 8
Lipolysis
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(role of acute-phase response, cytokines, hypermetabolism, energy expenditure, and ubiquitin proteasome proteolytic pathway in pathogenesis of cancer cachexia)
- IT Protein degradation
(ubiquitination; role of acute-phase response, cytokines, hypermetabolism, energy expenditure, and ubiquitin proteasome proteolytic pathway in pathogenesis of cancer cachexia)
- IT **10417-94-4, Eicosapentaenoic acid**
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(eicosapentaenoic acid as promising new treatment of cancer cachexia)
- IT 56-65-5, 5'-ATP, biological studies 60267-61-0, Ubiquitin 140879-24-9, Proteasome
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(role of acute-phase response, cytokines, hypermetabolism, energy expenditure, and ubiquitin proteasome proteolytic pathway in pathogenesis of cancer cachexia)

RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Anon; BMJ 1984, V289, P584
- (2) Attaix, D; Mol Biol Rep 1997, V24, P95 HCAPLUS
- (3) Baracos, V; N Engl J Med 1983, V308, P553 HCAPLUS
- (4) Barber, M; Br J Cancer 1999, V81, P80 HCAPLUS
- (5) Beck, S; Cancer Res 1991, V51, P6089 HCAPLUS
- (6) Biolo, G; Metabolism 2000, V49, P689 HCAPLUS
- (7) Bodine, S; Science 2001, V294, P1704 HCAPLUS
- (8) Costelli, P; Br J Cancer 2001, V84, P946 HCAPLUS
- (9) Deblaauw, I; Int J Cancer 1997, V71, P148 HCAPLUS
- (10) Downer, S; Br J Cancer 1993, V67, P1102 MEDLINE
- (11) Fischer, D; Shock 2001, V15, P200 MEDLINE
- (12) Gomes-Marcondes, M; Br J Cancer 2002, V86, P1628 HCAPLUS
- (13) Goodman, M; Am J Physiol 1991, V260, PE727 HCAPLUS
- (14) Hasselgren, P; Ann Surg 2001, V233, P9 MEDLINE
- (15) Jagoe, R; Clin Sci 2002, V102, P353 HCAPLUS

- (16) Li, Y; FASEB J 1998, V12, P871 HCAPLUS
- (17) Llovera, M; Cancer Lett 1998, V133, P83 HCAPLUS
- (18) Llovera, M; J Natl Cancer Inst 1993, V85, P1334 HCAPLUS
- (19) Lorite, M; Br J Cancer 1998, V78, P850 HCAPLUS
- (20) Lorite, M; Br J Cancer 2001, V85, P297 HCAPLUS
- (21) Macdonald, N; J Am Coll Surg 2003, V197, P143
- (22) Matthys, P; Eur J Cancer 1991, V27, P182 MEDLINE
- (23) Pratt, V; Br J Cancer 2002, V87, P1370 HCAPLUS
- (24) Rajapurohitam, V; Am J Physiol 2002, V282, PE739 HCAPLUS
- (25) Smith, H; Cancer Res 1999, V59, P5507 HCAPLUS
- (26) Tanaka, K; Biochem Biophys Res Commun 1998, V247, P537 HCAPLUS
- (27) Temparis, S; Cancer Res 1994, V54, P5568 HCAPLUS
- (28) Whitehouse, A; Cancer Res 2001, V61, P3604 HCAPLUS
- (29) Wigmore, S; Nutr Cancer 2000, V36, P177 HCAPLUS
- (30) Williams, A; Surgery 1999, V126, P744 MEDLINE
- (31) Zuijdgeest-van Leeuwen, S; Clin Nutr 2002, V21, P225 HCAPLUS


IT 10417-94-4, **Eicosapentaenoic acid**

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (eicosapentaenoic acid as promising new treatment
 of cancer cachexia)

RN 10417-94-4 HCAPLUS

CN 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (9CI) (CA INDEX
 NAME)

Double bond geometry as shown.



L46 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:373862 HCAPLUS

DN 136:51818

ED Entered STN: 24 May 2001

TI Cancer **anorexia** and cachexia

AU Tisdale, M. J.

CS Pharmaceutical Sciences Research Institute, Aston University, Birmingham,
 UK

SO Nutrition (New York, NY, United States) (2001), 17(5), 438-442

CODEN: NUTRER; ISSN: 0899-9007

PB Elsevier Science Inc.

DT Journal; General Review

LA English

CC 14-0 (Mammalian Pathological Biochemistry)

Section cross-reference(s): 1

AB A review. Patients with cancer cachexia experience a profound wasting of
 adipose tissue and lean body mass. **Anorexia**, although often
 present, is insufficient to account for tissue wasting because (1)
 cachexia involves massive depletion of skeletal muscle that does not occur
 during **anorexia**, (2) nutritional supplementation cannot
 replenish the loss of lean body mass, (3) cachexia can occur without
anorexia, and (4) food intake might be normal for the lower weight of
 the cancer patient. **Anorexia** can arise from (1) decreased taste
 and smell of food, (2) early satiety, (3) dysfunctional hypothalamic
 membrane adenylate cyclase, (4) increased brain tryptophan, and (5)
 cytokine production Appetite stimulants such as cyproheptadine,

medroxyprogesterone acetate, and megestrol acetate do not significantly improve lean body mass. Tumor products might be more important in the development of cachexia. Cachectic patients excrete in their urine a lipid-mobilizing factor that directly stimulates lipolysis in a cAMP-dependent manner and increases energy expenditure. Loss of skeletal muscle in cachexia is caused by upregulation of the ubiquitin-proteasome catabolic pathway. Cachexia-inducing tumors elaborate a sulfated glycoprotein, which directly initiates protein catabolism in skeletal muscle. The action of this proteolysis-inducing factor is attenuated by the polyunsatd. fatty acid **eicosapentaenoic acid**, which is also effective in preventing loss of skeletal muscle in cancer patients. Antagonists of tumor catabolic factors will provide important new agents in the treatment of cancer cachexia.

ST review protein metab feeding cancer **anorexia** cachexia; fatty acid **eicosapentaenoate** cancer cachexia **anorexia** review; adipose tissue muscle metab anticachectic cancer **anorexia** cachexia review

IT **Cachexia**
(cancerous, anticachectics; pathogenesis and treatment of cancer **anorexia** and cachexia)

IT Metabolism
(catabolic, of proteins; pathogenesis and treatment of cancer **anorexia** and cachexia)

IT **Body weight**
(loss; pathogenesis and treatment of cancer **anorexia** and cachexia)

IT Adipose tissue
(metabolism; pathogenesis and treatment of cancer **anorexia** and cachexia)

IT **Anorexia**
Energy metabolism, animal
Feeding
Muscle

(pathogenesis and treatment of cancer **anorexia** and cachexia)

IT Protein metabolism
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(pathogenesis and treatment of cancer **anorexia** and cachexia)

IT Fatty acids, biological studies
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyunsatd.; pathogenesis and treatment of cancer **anorexia** and cachexia)

IT **10417-94-4, Eicosapentaenoic acid**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pathogenesis and treatment of cancer **anorexia** and cachexia)

RE.CNT 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD


RE

- (1) Baracos, V; Am J Physiol 1995, V268, PE996 HCAPLUS
- (2) Barber, M; Br J Cancer 1999, V81, P80 HCAPLUS
- (3) Barber, M; Prostaglandins Leukot Essent Fatty Acids 1997, V57, P204
- (4) Beck, S; Cancer Res 1987, V47, P5919 HCAPLUS
- (5) Beck, S; Cancer Res 1991, V51, P6089 HCAPLUS
- (6) Belizario, J; Br J Cancer 1991, V63, P705 MEDLINE
- (7) Berg, M; Cytokine 1994, V6, P425 HCAPLUS
- (8) Bibby, M; J Natl Cancer Inst 1987, V78, P539 HCAPLUS
- (9) Bing, C; Cancer Res 2000, V60, P2405 HCAPLUS
- (10) Cangiano, C; J Natl Cancer Inst 1996, V88, P50
- (11) Cariuk, P; Br J Cancer 1997, V76, P606 MEDLINE
- (12) Chance, W; Brain Res 1995, V691, P180 HCAPLUS

- (13) Chance, W; Life Sci 1994, V54, P1869 HCAPLUS
- (14) Chance, W; Peptides 1996, V17, P797 HCAPLUS
- (15) Costa, G; Cancer Treat Rep 1981, V65(suppl 5), P3
- (16) Costa, G; Nutr Cancer 1980, V2, P98
- (17) Costa, G; Prog Exp Tumor Res 1963, V3, P321
- (18) De Wys, W; Cancer 1975, V36, P1888 MEDLINE
- (19) De Wys, W; Semin Oncol 1985, V12, P452 MEDLINE
- (20) Downer, S; Br J Cancer 1993, V67, P1102 MEDLINE
- (21) Drott, C; Clin Physiol 1989, V9, P427 MEDLINE
- (22) Ebisui, C; Clin Sci 1995, V89, P431 HCAPLUS
- (23) Edmonson, J; Cancer 1966, V19, P277 HCAPLUS
- (24) Emery, P; Br Med J 1984, V289, P584 MEDLINE
- (25) Espat, N; Am J Physiol 1996, V271, P185 HCAPLUS
- (26) Evans, W; Cancer Res 1985, V45, P3347 MEDLINE
- (27) Falconer, J; Ann Surg 1994, V219, P325 MEDLINE
- (28) Fearon, K; Proc Nutr Soc 1992, V51, P251 HCAPLUS
- (29) Fredrix, E; Cancer Res 1991, V51, P6138 MEDLINE
- (30) Gambardella, A; Metabolism 1994, V48, P291
- (31) Garcia-Martinez, C; Mol Cell Biochem 1993, V125, P11 HCAPLUS
- (32) Gogos, C; Cancer 1998, V82, P395 HCAPLUS
- (33) Goldberg, R; J Clin Oncol 1995, V13, P2856 HCAPLUS
- (34) Goll, D; Biochimie 1992, V74, P225 HCAPLUS
- (35) Grosvenor, M; Cancer 1989, V63, P330 MEDLINE
- (36) Groundwater, P; Br J Cancer 1990, V62, P816 MEDLINE
- (37) Hellerstein, M; J Clin Invest 1989, V84, P228 HCAPLUS
- (38) Hirai, K; Cancer Res 1998, V58, P2359 HCAPLUS
- (39) Hussey, H; Br J Cancer 1999, V80, P1231 HCAPLUS
- (40) Hyltander, A; Eur J Cancer 2000, V36, P330 HCAPLUS
- (41) Inui, A; Cancer Res 1999, V59, P4493 HCAPLUS
- (42) Jeevanandam, M; Lancet 1984, V1, P1423 MEDLINE
- (43) Kardinal, C; Cancer 1990, V65, P2657 MEDLINE
- (44) Khan, S; Int J Cancer 1999, V80, P444 HCAPLUS
- (45) Knox, L; Nurs Clin North Am 1983, V18, P97 MEDLINE
- (46) Kotler, D; JPEN 1990, V14, P454 MEDLINE
- (47) Laviano, A; Nutrition 1996, V12, P706 MEDLINE
- (48) Lecker, S; J Nutr 1999, V129, P227S HCAPLUS
- (49) Li, Y; FASEB J 1998, V12, P871 HCAPLUS
- (50) Llovera, M; Biochem Biophys Res Commun 1997, V230, P238 HCAPLUS
- (51) Llovera, M; Cancer Lett 1998, V133, P83 HCAPLUS
- (52) Loprinzi, C; J Natl Cancer Inst 1990, V82, P1127 MEDLINE
- (53) Lorite, M; Br J Cancer 1997, V76, P1035 HCAPLUS
- (54) Lorite, M; Br J Cancer 1998, V78, P850 HCAPLUS
- (55) Lovell, B; Ann Rev Med Chem 1997, V48, P307
- (56) Lundholm, K; Cancer Res 1982, V42, P4807 MEDLINE
- (57) Maltoni, M; Support Care Cancer 1997, V5, P130 MEDLINE
- (58) Moley, J; JPEN 1987, V11, P219 MEDLINE
- (59) Plata Salaman, C; Brain Res 1998, V448, P106
- (60) Price, S; Cancer Res 1998, V58, P4827 HCAPLUS
- (61) Rennie, M; Clin Physiol 1983, V3, P387 HCAPLUS
- (62) Scott, H; Br J Cancer 1996, V73, P1560 MEDLINE
- (63) Shaw, J; Ann Surg 1987, V205, P368 MEDLINE
- (64) Shellock, F; J Cancer Res Clin Oncol 1986, V111, P82 MEDLINE
- (65) Smith, H; Cancer Res 1999, V59, P5507 HCAPLUS
- (66) Smith, K; Br J Cancer 1993, V68, P314 HCAPLUS
- (67) Strang, P; Anticancer Res 1997, V17, P657 MEDLINE
- (68) Strent, S; J Trauma 1987, V27, P262
- (69) Temparis, S; Cancer Res 1994, V54, P5568 HCAPLUS
- (70) Thompson, M; Biochim Biophys Acta 1993, V1180, P236 HCAPLUS
- (71) Tisdale, M; Biochem Pharmacol 1991, V41, P103 HCAPLUS
- (72) Todorov, P; Br J Cancer 1999, V80, P1734 HCAPLUS

(73) Todorov, P; Cancer Res 1996, V56, P1256 HCAPLUS
 (74) Todorov, P; Cancer Res 1998, V58, P2353 HCAPLUS
 (75) Todorov, P; J Biol Chem 1997, V272, P12279 HCAPLUS
 (76) Todorov, P; Nature (Lond) 1996, V379, P739 HCAPLUS
 (77) Tracey, K; J Clin Invest 1990, V86, P2014 HCAPLUS
 (78) Vigano, A; Cancer Surv 1994, V21, P99 HCAPLUS
 (79) Wigmore, S; Br J Surg 2000, V87, P53 MEDLINE
 (80) Wigmore, S; Nutrition 1996, V12(suppl), PS27
 IT **10417-94-4, Eicosapentaenoic acid**
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (pathogenesis and treatment of cancer **anorexia** and cachexia)
 RN 10417-94-4 HCAPLUS
 CN 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (9CI) (CA INDEX
 NAME)

Double bond geometry as shown.



L46 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN **2000:856297** HCAPLUS
 DN 134:264084
 ED Entered STN: 07 Dec 2000
 TI Metabolic abnormalities in cachexia and **anorexia**
 AU Tisdale, Michael J.
 CS Pharmaceutical Sciences Research Institute, Aston University, Birmingham,
 UK
 SO Nutrition (New York) (2000), 16(10), 1013-1014
 CODEN: NUTRER; ISSN: 0899-9007
 PB Elsevier Science Inc.
 DT Journal; General Review
 LA English
 CC 14-0 (Mammalian Pathological Biochemistry)
 AB A review with 34 refs. An increased glucose requirement by many solid
 tumors produces an increased metabolic demand on the liver, resulting in
 an increased energy expenditure. In addition, several cytokines and tumor
 catabolic products have been suggested as being responsible for the
 depletion of adipose tissue and skeletal-muscle mass in cachexia. A
 sulfated glycoprotein of mol. mass 24 kDa, produced by cachexia-inducing
 tumors and present in the urine of cancer patients actively losing weight,
 has been shown to be capable of inducing direct muscle catabolism in vitro
 and a state of cachexia in vivo, with specific loss of the non-fat carcass
 mass. In vitro studies have shown the bioactivity of this
 proteolysis-inducing factor to be attenuated by the polyunsatd. fatty
 acid, **eicosapentaenoic acid**. Preliminary clin.
 studies have shown that **eicosapentaenoic acid**
 stabilizes body weight and protein and fat reserves in patients with
 pancreatic carcinoma. Further trials are required to confirm the efficacy
 of **eicosapentaenoic acid** and to determine the anticachectic
 activity in other types of cancer.
 ST review metabolic abnormality cachexia **anorexia**
 IT **Cachexia**
 (cancerous; metabolic abnormalities in cachexia and **anorexia**
 in humans and laboratory animals)

IT Metabolism, animal
(disorder; metabolic abnormalities in cachexia and anorexia
in humans and laboratory animals)

IT Anorexia
(metabolic abnormalities in cachexia and anorexia in humans
and laboratory animals)

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Beck, S; Br J Cancer 1990, V62, P822 MEDLINE
- (2) Beck, S; Cancer Res 1991, V51, P6089 HCAPLUS
- (3) Belizario, J; Br J Cancer 1991, V63, P705 MEDLINE
- (4) Brennan, M; Cancer Res 1986, V37, P2359
- (5) Costa, G; Cancer Res 1962, V22, P1081 HCAPLUS
- (6) Costa, G; Cancer Treat Rep 1981, V65, P3
- (7) De Wys, W; Clinics in oncology 1986, V5, P251
- (8) Drott, C; Clin Physiol 1989, V9, P427 MEDLINE
- (9) Emery, P; Br Med J 1984, V289, P584 MEDLINE
- (10) Falconer, J; Ann Surg 1994, V219, P325 MEDLINE
- (11) Fredrix, E; Cancer Res 1991, V51, P6138 MEDLINE
- (12) Groundwater, P; Br J Cancer 1990, V62, P816 MEDLINE
- (13) Holm, E; Cancer Res 1995, V5, P1373
- (14) Holroyde, C; Cancer Res 1975, V35, P3710 HCAPLUS
- (15) Kitada, S; Lipids 1980, V15, P168 HCAPLUS
- (16) Kralovic, R; Eur J Cancer 1977, V13, P1071 HCAPLUS
- (17) Lahdevirta, J; Am J Med 1988, V85, P289 MEDLINE
- (18) Lorite, M; Br J Cancer 1997, V76, P1035 HCAPLUS
- (19) Lundholm, K; Cancer 1982, V50, P1142 MEDLINE
- (20) Lundholm, K; Cancer Res 1979, V39, P1968
- (21) Lundholm, K; Eur J Cancer 1976, V12, P465 HCAPLUS
- (22) Nixon, D; Am J Med 1980, V68, P683 MEDLINE
- (23) Smith, K; Br J Cancer 1993, V67, P680 HCAPLUS
- (24) Tang, D; Proc Natl Acad Sci USA 1996, V93, P5241 HCAPLUS
- (25) Tayek, J; J Am Coll Nutr 1992, V11, P445 MEDLINE
- (26) Taylor, D; Cancer Res 1992, V52, P829 HCAPLUS
- (27) Temparis, S; Cancer Res 1994, V54, P5568 HCAPLUS
- (28) Thompson, M; Biochim Biophys Acta 1993, V1180, P236 HCAPLUS
- (29) Tisdale, M; Biochem Pharmacol 1991, V41, P103 HCAPLUS
- (30) Tisdale, M; Cancer Res 1987, V47, P5919
- (31) Todorov, P; Cancer Res 1996, V56, P1256 HCAPLUS
- (32) Todorov, P; J Biol Chem 1997, V272, P12279 HCAPLUS
- (33) Todorov, P; Nature 1996, V379, P739 HCAPLUS
- (34) Wigmore, S; Nutrition 1996, V12, P27 MEDLINE

L46 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2000:415524 HCAPLUS

DN 133:22406

ED Entered STN: 22 Jun 2000

TI Method for the prevention and treatment of cachexia and anorexia

IN Abbruzzese, Bonnie Chandler; McCamish, Mark Anthony; Cope, Frederick
Oliver; Demichele, Stephen Joseph

PA Abbott Laboratories, USA

SO U.S., 12 pp., Cont.-in-part of U. S. Ser. No. 635,179, abandoned.
CODEN: USXXAM

DT Patent

LA English

IC ICM A23J0003-16

ICS A61K0038-17

INCL 514021000

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 17, 18

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6077828	A	20000620	US 1997-842454	19970424
	CA 2252513	AA	19971030	CA 1997-2252513	19970425
	CA 2252513	C	20021119		
	CA 2355247	AA	19971030	CA 1997-2355247	19970425
	CA 2355247	C	20021126		
	WO 9739749	A2	19971030	WO 1997-US6897	19970425
	WO 9739749	A3	19971204		
	W: AU, CA, JP, MX, NZ				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9727424	A1	19971112	AU 1997-27424	19970425
	AU 716532	B2	20000224		
	EP 914111	A2	19990512	EP 1997-921367	19970425
	EP 914111	B1	20031119		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
	JP 11508282	T2	19990721	JP 1997-538345	19970425
	NZ 332291	A	20000728	NZ 1997-332291	19970425
	NZ 504416	A	20010525	NZ 1997-504416	19970425
	AT 254454	E	20031215	AT 1997-921367	19970425
	PT 914111	T	20040430	PT 1997-921367	19970425
	EP 1415650	A1	20040506	EP 2003-26561	19970425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
	ES 2210523	T3	20040701	ES 1997-921367	19970425
	MX 9808867	A	20000531	MX 1998-8867	19981023
	HK 1019857	A1	20041105	HK 1999-105140	19991109
	US 6326355	B1	20011204	US 2000-479550	20000107
	US 6387883	B1	20020514	US 2000-642630	20000818
	US 2002099020	A1	20020725	US 2001-2179	20011205
	US 2004167081	A1	20040826	US 2004-784451	20040223
PRAI	US 1996-635179	B2	19960425		
	US 1997-842454	A	19970424		
	CA 1997-2252513	A3	19970425		
	EP 1997-921367	A3	19970425		
	NZ 1997-332291	A1	19970425		
	WO 1997-US6897	W	19970425		
	US 2000-479550	A1	20000107		
	US 2000-642630	A1	20000818		
	US 2001-2179	A1	20011205		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 6077828	ICM	A23J0003-16
	ICS	A61K0038-17
	INCL	514021000
	IPCI	A23J0003-16 [ICM,7]; A61K0038-17 [ICS,7]
	IPCR	A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A]; A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305 [I,C]
	NCL	514/021.000; 424/523.000; 426/072.000; 426/601.000; 426/602.000; 426/656.000; 426/800.000; 426/801.000; 514/578.000; 514/725.000; 514/730.000; 514/739.000
	ECLA	A23L001/29F; A23L001/30C2; A23L001/304; A23L001/305A
CA 2252513	IPCI	A61K0031-20 [ICM,6]; A61K0038-01 [ICS,6]; A23L0001-30 [ICS,6]; A61K0031-375 [ICS,6]
CA 2355247	IPCI	A61K0031-20 [ICM,7]; A61K0031-015 [ICS,7]; A61K0033-04 [ICS,7]; A61P0003-04 [ICS,7]; A23L0001-302 [ICS,7]; A61K0031-355 [ICS,7]; A61K0031-375 [ICS,7]

WO 9739749	IPCI	A61K0031-20 [ICM,6]
	IPCR	A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A]; A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305 [I,C]
AU 9727424	ECLA	A23L001/29F; A23L001/30C2; A23L001/304; A23L001/305A
	IPCI	A61K0031-20 [ICM,6]
	IPCR	A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A]; A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305 [I,C]
EP 914111	IPCI	A61K0031-20 [ICM,6]
	IPCR	A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A]; A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305 [I,C]
JP 11508282	IPCI	A61K0031-20 [ICM,6]; A61K0031-015 [ICS,6]; A61K0031-195 [ICS,6]; A61K0031-355 [ICS,6]; A61K0031-375 [ICS,6]; A61K0033-04 [ICS,6]; A61K0045-00 [ICS,6]
	IPCR	A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A]; A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305 [I,C]
NZ 332291	IPCI	A61K0031-20 [ICM,7]
	IPCR	A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A]; A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305 [I,C]
NZ 504416	IPCI	A61K0031-20 [ICM,7]
	IPCR	A61K0031-185 [I,C]; A61K0031-20 [I,A]
AT 254454	IPCI	A61K0031-20 [ICM,7]; A61P0003-04 [ICS,7]
PT 914111	IPCI	A61K0031-20 [ICM,7]; A61P0003-04 [ICS,7]
EP 1415650	IPCI	A61K0031-20 [ICM,7]; A61K0031-195 [ICS,7]; A61K0031-00 [ICS,7]
	ECLA	A23L001/30C2; A23L001/305A; A23L001/29F
ES 2210523	IPCI	A61K0031-20 [ICM,7]; A61P0003-04 [ICS,7]
	IPCR	A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A]; A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305 [I,C]
MX 9808867	IPCI	A61K0031-20 [ICM,5]
HK 1019857	IPCI	A61K [ICM,7]; A61P [ICS,7]
US 6326355	IPCI	A23J0003-16 [ICM,7]; A61K0038-17 [ICS,7]
	IPCR	A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A]; A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305 [I,C]
	NCL	514/021.000; 424/523.000; 426/072.000; 426/601.000; 426/602.000; 426/656.000; 426/800.000; 426/801.000; 514/578.000; 514/725.000; 514/730.000; 514/739.000
	ECLA	A23L001/29F; A23L001/30C2; A23L001/304; A23L001/305A
US 6387883	IPCI	A23J0003-16 [ICM,7]; A61K0038-17 [ICS,7]
	IPCR	A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A]; A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305 [I,C]
	NCL	514/021.000; 424/523.000; 426/072.000; 426/601.000; 426/602.000; 426/656.000; 426/800.000; 426/801.000; 514/578.000; 514/725.000; 514/730.000; 514/739.000
	ECLA	A23L001/29F; A23L001/30C2; A23L001/304; A23L001/305A

US 2002099020 IPCI A61K0038-00 [ICM,7]; A61K0031-355 [ICS,7]; A61K0031-375 [ICS,7]; A61K0031-015 [ICS,7]; A61K0033-04 [ICS,7]
 IPCR A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A]; A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305 [I,C]
 NCL 514/021.000
 ECLA A23L001/29F; A23L001/30C2; A23L001/304; A23L001/305A
 US 2004167081 IPCI A61K0031-70 [ICM,7]; A61K0031-20 [ICS,7]
 IPCR A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A]; A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305 [I,C]
 NCL 514/023.000
 ECLA A23L001/29F; A23L001/30C2; A23L001/304; A23L001/305A
 AB The present invention relates to methods and nutritional compns. for the prevention and treatment of cachexia and **anorexia**. The methods of the invention comprise administering a composition comprising effective amts. of ω -3 fatty acids such as alpha-linolenic acid, stearidonic acid, **eicosapentaenoic acid**, docosapentaenoic acid, docosahexaenoic acid or mixts. thereof; of branched-chain amino acids valine, leucine, isoleucine or mixts. thereof, with or without reduced levels of tryptophan and 5-hydroxytryptophan, and of an antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixts. thereof.
 ST diet therapeutic **anorexia** cachexia
 IT Amino acids, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (branched; therapeutic diet for prevention and treatment of cachexia and **anorexia**)
 IT Fats and Glyceridic oils, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (fish; therapeutic diet for prevention and treatment of cachexia and **anorexia**)
 IT Glycerides, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (medium-chain; therapeutic diet for prevention and treatment of cachexia and **anorexia**)
 IT Fatty acids, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (polyunsatd., omega-3; therapeutic diet for prevention and treatment of cachexia and **anorexia**)
 IT Fatty acids, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (polyunsatd., omega-6; therapeutic diet for prevention and treatment of cachexia and **anorexia**)
 IT Lecithins
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (soya; therapeutic diet for prevention and treatment of cachexia and **anorexia**)
 IT **Anorexia**
 Antioxidants
Cachexia
 (therapeutic diet for prevention and treatment of cachexia and


anorexia)
 IT Canola oil
 Lecithins
 Soybean oil
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (therapeutic diet for prevention and treatment of cachexia and **anorexia)**
 IT Diet
 (therapeutic; therapeutic diet for prevention and treatment of cachexia and **anorexia)**
 IT 50-81-7, Vitamin C, biological studies 61-90-5, L-Leucine, biological studies 72-18-4, L-Valine, biological studies 73-32-5, L-Isoleucine, biological studies 463-40-1, α -Linolenic acid 1406-18-4, Vitamin E 6217-54-5, Cervonic acid 7235-40-7, β -Carotene 7782-49-2, Selenium, biological studies **10417-94-4, Timnodonic acid** 20290-75-9, Stearidonic acid 32839-34-2, Docosapentaenoic acid
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (therapeutic diet for prevention and treatment of cachexia and **anorexia)**

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Anon; 1990
- (2) Anon; EP 0367724 1990 HCAPLUS
- (3) Anon; DE 3901048 1990
- (4) Anon; EP 0462398 1991 HCAPLUS
- (5) Anon; WO 9508349 1995 HCAPLUS
- (6) Anon; EP 0756827 1996 HCAPLUS
- (7) Anon; WO 9713415 1997 HCAPLUS
- (8) Anon; Build Bulk and Muscle for that Competitive Edge 1996
- (9) Anon; no publication given 1990
- (10) Anon; no publication given 1996
- (11) Anon; no publication given 1996
- (12) Anon; no publication given 1996
- (13) Bozzetti, F; Journal of Parenteral and Enteral Nutrition 1989, V13(4), P406 MEDLINE
- (14) Cangiano, C; Anticancer Research 1994, V14, P1451 MEDLINE
- (15) Cangiano, C; J Neural Transm (GenSect 1990, V81, P225 MEDLINE
- (16) Cho; Lipid peroxidation and antioxidant status is affected by different vitamin E levels when feeding fish oil 1994 HCAPLUS
- (17) Cope; US 5330972 1994 HCAPLUS
- (18) Demichele; US 5223285 1993 HCAPLUS
- (19) Dinarello, C; Annals of The New York Academy of Sciences 1990, V587, P332 HCAPLUS
- (20) Garleb; US 5308832 1994 HCAPLUS
- (21) Garleb; US 5444054 1995 HCAPLUS
- (22) Heber, D; Journal of Parenteral and Enteral Nutrition 1992, V16(6, Supplement), P60S
- (23) Henderson, R; Lipids 1992, V27(11), P863 HCAPLUS
- (24) Keller, U; Supportive Care in Cancer 1993, V1, P209
- (25) Kern, K; Journal of Parental and Enteral Nutrition 1988, V12(3), P286 MEDLINE
- (26) Krause, R; Cancer 1979, V44, P1003 HCAPLUS
- (27) McNamara, M; Journal of Parenteral and Enteral Nutrition 1992, V16(6, Supplement), P50S
- (28) Meguid, M; Journal of Parenteral and Enteral Nutrition 1992, V16(6, Supplement), P59S
- (29) Ohmori; US 5431925 1995 HCAPLUS

- (30) Ottery, F; Cancer Practice 1994, V2(2), P123 MEDLINE
 (31) Ottery, F; Seminars in Oncology 1995, V22(2, Supplement 3), P98
 (32) Richardson; US 5393784 1995 HCAPLUS
 (33) Ross-Fanelli, F; Nutrition 1991, V7(5)
 (34) Rossi-Fanelli, F; 1986, V22(1), P89 MEDLINE
 (35) Seto; US 4615839 1986 HCAPLUS
 (36) Tisdale; US 5385740 1995 HCAPLUS
 (37) Tisdale; US 5457130 1995 HCAPLUS
 (38) Tisdale, M; Anti Cancer Drugs 1993, V4, P113
 (39) Tisdale, M; Cancer Research 1990, V50, P5022 HCAPLUS
 (40) Tisdale, M; Nutrition 1996, V12, PS31 MEDLINE
 (41) Todorov, P; Nature 1996, V379, P739 HCAPLUS
 (42) Utesjev; immunomodulating and antioxidant effect of beta-carotene and essential fatty acids in disturbed lipid metabolism 1998 HCAPLUS
 (43) Wigmore, S; Nutrition 1996, V12(1), PS27
 IT 10417-94-4, **Timnodonic acid**
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (therapeutic diet for prevention and treatment of cachexia and **anorexia**)
 RN 10417-94-4 HCAPLUS
 CN 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



- L46 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 1999:61519 HCAPLUS
 DN 130:222473
 ED Entered STN: 01 Feb 1999
 TI Wasting in cancer
 AU Tisdale, Michael J.
 CS Pharmaceutical Sciences Institute, Aston University, Birmingham, B4 7ET, UK
 SO Journal of Nutrition (1999), 129(1S), 243S-246S
 CODEN: JONUAI; ISSN: 0022-3166
 PB American Society for Nutritional Sciences
 DT Journal; General Review
 LA English
 CC 18-0 (Animal Nutrition)
 Section cross-reference(s): 14
 AB A review with 47 refs. Progressive weight loss is a common feature of many types of cancer and is responsible not only for a poor quality of life and poor response to chemotherapy, but also a shorter survival time than is found in patients with comparable tumors without weight loss. Although **anorexia** is common, a decreased food intake alone is unable to account for the changes in body composition seen in cancer patients, and increasing nutrient intake is unable to reverse the wasting syndrome. Although energy expenditure is increased in some patients, cachexia can occur even with a normal energy expenditure. Various factors have been investigated as mediators of tissue wasting in cachexia. These include cytokines such as tumor necrosis factor- α (TNF- α), interleukin-6 (IL-6), interferon- γ (IFN- γ) and leukemia

inhibitory factor (LIF), as well as tumor-derived factors such as lipid mobilizing factor (LMF) and protein mobilizing factor (PMF), which can directly mobilize fatty acids and amino acids from adipose tissue and skeletal muscle resp. Induction of lipolysis by the cytokines is thought to result from an inhibition of lipoprotein lipase (LPL), although clin. studies provide no evidence for an inhibition of LPL in the adipose tissue of cancer patients. Instead there is an increased expression of hormone sensitive lipase, the enzyme activated by LMF. Protein degradation in cachexia is associated with an increased activity of the ATP-ubiquitin-proteasome pathway. The biol. activity of both the LMF and PMF was shown to be attenuated by **eicosapentaenoic acid (EPA)**. Clin. studies show that this polyunsatd. fatty acid is able to stabilize the rate of weight loss and adipose tissue and muscle mass in cachectic patients with unresectable pancreatic cancer. Knowledge of the mechanism of cancer cachexia should lead to the development of new therapeutic agents.

ST review cancer wasting cachexia

IT **Cachexia**

(cancerous; factors mediating wasting in cancer)

IT Diet

Energy metabolism, animal

(factors mediating wasting in cancer in relation to)

IT Disease, animal

(wasting; factors mediating wasting in cancer)

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Beck, S; Br J Cancer 1990, V62, P822 MEDLINE
- (2) Beck, S; Cancer Res 1987, V47, P5919 HCAPLUS
- (3) Costa, G; Cancer Treat Rep 1981, V65(Suppl 5), P3
- (4) Costelli, P; J Clin Invest 1993, V92, P2783 HCAPLUS
- (5) DeWys, W; Am J Med 1980, V69, P491 MEDLINE
- (6) DeWys, W; Cancer 1972, V45, P2013
- (7) Drott, C; Clin Physiol 1989, V9, P427 MEDLINE
- (8) Ebisui, C; Clin Sci 1995, V89, P431 HCAPLUS
- (9) Evans, W; Cancer Res 1985, V45, P3347 MEDLINE
- (10) Falconer, J; Ann Surg 1994, V121, P325 MEDLINE
- (11) Fearon, K; Cancer Res 1988, V48, P2590 MEDLINE
- (12) Fredix, E; Cancer Res 1991, V51, P6138
- (13) Fredix, E; Eur J Clin Nutr 1990, V44, P749
- (14) Goldberg, A; J Clin Invest 1988, V81, P1378 HCAPLUS
- (15) Grosvenor, M; Cancer 1989, V63, P330 MEDLINE
- (16) Groundwater, P; Br J Cancer 1990, V62, P816 MEDLINE
- (17) Grunfeld, C; Am J Med 1989, V86, P27 MEDLINE
- (18) Grunfeld, C; Trends Endocrinol Metabol 1991, V2, P213 HCAPLUS
- (19) Hauner, H; Diabetologica 1995, V38, P764 HCAPLUS
- (20) Heber, D; Cancer Res 1982, V42, P4815 MEDLINE
- (21) Kardinal, C; Cancer 1990, V65, P2657 MEDLINE
- (22) Kitada, S; Lipids 1980, V15, P168 HCAPLUS
- (23) Knox, C; Ann Surg 1983, V197, P152
- (24) Llovera, M; Biochim Biophys Res Commun 1997, V230, P238 HCAPLUS
- (25) Llovera, M; FEBS Lett 1994, V338, P311 HCAPLUS
- (26) Llovera, M; J Natl Cancer Inst 1993, V85, P1334 HCAPLUS
- (27) Loprinzi, C; J Clin Oncol 1993, V11, P152 MEDLINE
- (28) Loprinzi, C; J Clin Oncol 1993, V11, P762 MEDLINE
- (29) Lundholm, K; Eur J Cancer 1976, V12, P465 HCAPLUS
- (30) Marshall, M; Endocrinology 1994, V135, P141 HCAPLUS
- (31) Masuno, H; Cancer Res 1981, V41, P284 HCAPLUS
- (32) McMillan, D; Br J Surg 1994, V81, P1011 MEDLINE
- (33) Morrison, S; Physiol Behav 1976, V17, P705 MEDLINE
- (34) Nixon, D; Am J Med 1980, V68, P683 MEDLINE

- (35) Nixon, D; Metabolism 1988, V37, P1059 MEDLINE
- (36) Oversen, L; J Clin Oncol 1993, V11, P2043
- (37) Palomares, M; Cancer 1996, V78, P2119 MEDLINE
- (38) Rofo, A; Anticancer Res 1994, V14, P647 MEDLINE
- (39) Shaw, J; Ann Surg 1987, V205, P368 MEDLINE
- (40) Smith, K; Br J Cancer 1993, V68, P314 HCAPLUS
- (41) Strassman, G; Cytokines Mol Ther 1995, V1, P107
- (42) Thompson, M; Biochim Biophys Acta 1993, V1180, P236 HCAPLUS
- (43) Tisdale, M; Biochem Pharmacol 1991, V41, P103 HCAPLUS
- (44) Todorov, P; Cancer Res 1996, V56, P1256 HCAPLUS
- (45) Todorov, P; Nature 1996, V379, P739 HCAPLUS
- (46) Wigmore, S; Br J Cancer 1997, V75, P106 MEDLINE
- (47) Wigmore, S; Nutrition 1996, V12(Suppl), PS27

L46 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 1997:717812 HCAPLUS

DN 127:362629

ED Entered STN: 13 Nov 1997

TI Method for the prevention and treatment of cachexia and **anorexia**

IN Abbruzzese, Bonnie Chandler; McCamish, Mark Anthony; Cope, Frederick
Oliver; Demichele, Stephen Joseph

PA Abbott Laboratories, USA

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K0031-20

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 18

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9739749	A2	19971030	WO 1997-US6897	19970425
	WO 9739749	A3	19971204		
	W: AU, CA, JP, MX, NZ				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6077828	A	20000620	US 1997-842454	19970424
	AU 9727424	A1	19971112	AU 1997-27424	19970425
	AU 716532	B2	20000224		
	EP 914111	A2	19990512	EP 1997-921367	19970425
	EP 914111	B1	20031119		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
	JP 11508282	T2	19990721	JP 1997-538345	19970425
	NZ 332291	A	20000728	NZ 1997-332291	19970425
	AT 254454	E	20031215	AT 1997-921367	19970425
	MX 9808867	A	20000531	MX 1998-8867	19981023
	HK 1019857	A1	20041105	HK 1999-105140	19991109
PRAI	US 1996-635179	A	19960425		
	US 1997-842454	A	19970424		
	WO 1997-US6897	W	19970425		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 9739749	ICM	A61K0031-20
	IPCI	A61K0031-20 [ICM,6]
	IPCR	A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A]; A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305 [I,C]
	ECLA	A23L001/29F; A23L001/30C2; A23L001/304; A23L001/305A

US 6077828 IPCI A23J0003-16 [ICM,7]; A61K0038-17 [ICS,7]
 IPCR A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30
 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A];
 A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305
 [I,C]
 NCL 514/021.000; 424/523.000; 426/072.000; 426/601.000;
 426/602.000; 426/656.000; 426/800.000; 426/801.000;
 514/578.000; 514/725.000; 514/730.000; 514/739.000
 ECLA A23L001/29F; A23L001/30C2; A23L001/304; A23L001/305A
 AU 9727424 IPCI A61K0031-20 [ICM,6]
 IPCR A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30
 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A];
 A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305
 [I,C]
 EP 914111 IPCI A61K0031-20 [ICM,6]
 IPCR A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30
 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A];
 A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305
 [I,C]
 JP 11508282 IPCI A61K0031-20 [ICM,6]; A61K0031-015 [ICS,6]; A61K0031-195
 [ICS,6]; A61K0031-355 [ICS,6]; A61K0031-375 [ICS,6];
 A61K0033-04 [ICS,6]; A61K0045-00 [ICS,6]
 IPCR A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30
 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A];
 A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305
 [I,C]
 NZ 332291 IPCI A61K0031-20 [ICM,7]
 IPCR A23L0001-29 [I,A]; A23L0001-29 [I,C]; A23L0001-30
 [I,A]; A23L0001-30 [I,C]; A23L0001-304 [I,A];
 A23L0001-304 [I,C]; A23L0001-305 [I,A]; A23L0001-305
 [I,C]
 AT 254454 IPCI A61K0031-20 [ICM,7]; A61P0003-04 [ICS,7]
 MX 9808867 IPCI A61K0031-20 [ICM,5]
 HK 1019857 IPCI A61K [ICM,7]; A61P [ICS,7]
 AB The present invention relates to methods and nutritional compns. for the
 prevention and treatment of cachexia and **anorexia**. The methods
 comprise administering a composition containing effective amts. of (1) ω -3
 fatty acids, such as α -linolenic acid, stearidonic acid,
eicosapentaenoic acid, docosapentaenoic acid,
 docosahexaenoic acid or mixts. thereof, (2) branched-chain amino acids,
 such as valine, leucine, isoleucine or mixts. thereof, with or without
 reduced levels of tryptophan and 5-hydroxytryptophan, and (3) antioxidant
 system selected from the group comprising β -carotene, vitamin C,
 vitamin E, selenium, or mixts. thereof.
 ST enteral nutrient antioxidant **anorexia** cachexia
 IT Amino acids, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological
 study); USES (Uses)
 (branched; enteral compns. containing oil blend and amino acids and
 antioxidants for treatment of cachexia and **anorexia**)
 IT **Anorexia**
Cachexia
 Immunostimulants
 (enteral compns. containing oil blend and amino acids and antioxidants for
 treatment of cachexia and **anorexia**)
 IT Canola oil
 Soybean oil
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological
 study); USES (Uses)
 (enteral compns. containing oil blend and amino acids and antioxidants for

treatment of cachexia and **anorexia**)

IT Nutrients
(enteral; enteral compns. containing oil blend and amino acids and antioxidants for treatment of cachexia and **anorexia**)

IT Drug delivery systems
(enteric; enteral compns. containing oil blend and amino acids and antioxidants for treatment of cachexia and **anorexia**)

IT Fats and Glyceridic oils, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fish; enteral compns. containing oil blend and amino acids and antioxidants for treatment of cachexia and **anorexia**)

IT Antitumor agents
(for enhancing transport and efficacy; enteral compns. containing oil blend and amino acids and antioxidants for treatment of cachexia and **anorexia**)

IT Glycerides, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medium-chain; enteral compns. containing oil blend and amino acids and antioxidants for treatment of cachexia and **anorexia**)

IT Fatty acids, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyunsatd., n-3; enteral compns. containing oil blend and amino acids and antioxidants for treatment of cachexia and **anorexia**)

IT Fatty acids, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyunsatd., omega-6; enteral compns. containing oil blend and amino acids and antioxidants for treatment of cachexia and **anorexia**)

IT Lecithins
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soya; enteral compns. containing oil blend and amino acids and antioxidants for treatment of cachexia and **anorexia**)

IT 73-22-3, L-Tryptophan, biological studies 4350-09-8, L-5-HydroxyTryptophan
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(at limited amount; enteral compns. containing oil blend and amino acids and antioxidants for treatment of cachexia and **anorexia**)

IT 50-81-7, Vitamin C, biological studies 61-90-5, L-Leucine, biological studies 72-18-4, L-Valine, biological studies 73-32-5, L-Isoleucine, biological studies 463-40-1 1406-18-4, Vitamin E 6217-54-5, Docosahexaenoic acid 7235-40-7, β -Carotene 7782-49-2, Selenium, biological studies **10417-94-4, Eicosapentaenoic acid** 20290-75-9, Stearidonic acid 32839-34-2, Docosapentaenoic acid
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enteral compns. containing oil blend and amino acids and antioxidants for treatment of cachexia and **anorexia**)


IT **10417-94-4, Eicosapentaenoic acid**
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(enteral compns. containing oil blend and amino acids and antioxidants for treatment of cachexia and **anorexia**)

RN 10417-94-4 HCAPLUS

CN 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (9CI) (CA INDEX

NAME)

Double bond geometry as shown.



L46 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 1993:514455 HCAPLUS
 DN 119:114455
 ED Entered STN: 18 Sep 1993
 TI Cancer cachexia
 AU Tisdale, M. J.
 CS Pharm. Sci. Inst., Aston Univ., Birmingham, B4 7ET, UK
 SO Anti-Cancer Drugs (1993), 4(2), 115-25
 CODEN: ANTDEV; ISSN: 0959-4973
 DT Journal; General Review
 LA English
 CC 14-0 (Mammalian Pathological Biochemistry)
 AB A review with 102 refs. Cachexia is a common problem in the clin. management of cancer patients, particularly those with solid tumors. Cachexia is manifested as weight loss with a massive depletion of both adipose tissues and muscle mass, and death is probably due to the loss of lean body tissue. The survival time is shorter in patients with cachexia and the responses to chemotherapy are also reduced. Although **anorexia** frequently accompanies cachexia, attempts to halt or reverse cachexia by nutritional repletion have not been successful. The cancer cachexia may be due to metabolic abnormalities produced by the tumor in addition to the underlying **anorexia**. In some patients the weight loss is associated with an increased relative energy expenditure, possibly through an elevated adrenergic state. Several factors have been postulated as mediators of cancer cachexia and can include substances with hormone-like characteristics which cause direct catabolism of host tissues or cytokines which cause alterations in host metabolism indirectly. There are the conventional catabolic hormones and a lipid-mobilizing factor (LMF) produced by tumors which cause a direct breakdown of the adipose tissue. Tumor necrosis factor- α , interleukin-6, interferon- γ , and leukemia inhibitory factor are examples of possibly cachexia-related cytokines. The substances may influence the adipose tissue indirectly through an inhibition of lipoprotein lipase. The reversal of cachexia has been achieved by agents stimulating food intake, e.g. megestrol acetate, or directly inhibiting LMF, e.g. **eicosapentaenoic acid**. While agents in the first group can stimulate tumor growth, those in the second group act as tumor growth inhibitors. The products of catabolism of host tissues may be important for tumor growth and chemotherapeutic intervention.

ST review cancer cachexia mechanism
 IT Neoplasm
 (cachexia in humans with, mechanisms of)
 IT **Cachexia**
 (in cancer, mechanisms of, in humans)

=> => fil medline

FILE 'MEDLINE' ENTERED AT 11:30:07 ON 10 MAY 2006

FILE LAST UPDATED: 9 MAY 2006 (20060509/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).

See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his 156-

(FILE 'REGISTRY' ENTERED AT 11:24:39 ON 10 MAY 2006)

FILE 'HCAPLUS' ENTERED AT 11:24:51 ON 10 MAY 2006

FILE 'MEDLINE' ENTERED AT 11:26:18 ON 10 MAY 2006

```
L56      2311 S L9 OR L10 OR L50 OR L34 OR L35
L57      3876 S L4 OR L12
L58      3877 S L56,L57
L59      21444 S L19 OR L21
          E ANOREXIA/CT
          E E3+ALL
L60      2730 S E5+NT
          E E8+ALL
L61      7839 S E4+NT
          E E3+ALL
L62      14422 S E3+NT
          E BULIMIA/CT
          E E3+ALL
L63      4008 S E6+NT OR E11+NT
L64      22 S L58 AND L59-L63
L65      9 S L64 AND PY<=2002
L66      13 S L64 NOT L65
L67      3 S L66 AND 2003/PY
L68      12 S L65,L67
```

FILE 'MEDLINE' ENTERED AT 11:30:07 ON 10 MAY 2006

=> d all tot 168

```
L68  ANSWER 1 OF 12      MEDLINE on STN
AN   2004429536      MEDLINE
DN   PubMed ID: 15334872
TI   Pathogenesis of cancer cachexia.
AU   Tisdale Michael J
CS   Pharmaceutical Sciences Research Institute, Aston University, Aston
     Triangle, Birmingham, United Kingdom.. m.j.tisdale@aston.ac.uk
SO   The journal of supportive oncology, (2003 Sep-Oct) Vol. 1, No.
```

3, pp. 159-68. Ref: 62
Journal code: 101181305. ISSN: 1544-6794.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LA English

FS Priority Journals

EM 200410

ED Entered STN: 1 Sep 2004

Last Updated on STN: 29 Oct 2004

Entered Medline: 28 Oct 2004

AB Cachexia is a progressive wasting syndrome characterized by extensive loss of adipose tissue and skeletal muscle. It occurs in about half of all cancer patients. While **anorexia** also may be present, the energy deficit alone does not explain the pathogenesis of cachexia. The presence of an acute phase response (APR) has been linked to accelerated weight loss and a shortened survival time. The APR is thought to be initiated by cytokines such as interleukin (IL)-6 and IL-8, production of which is induced by a tumor factor, proteolysis inducing factor (PIF). Cachectic cancer patients also show an increased expression of uncoupling protein-3 in muscle, which may act as an energy sink, increasing energy expenditure. Loss of adipose tissue appears to be due to an increase in degradation of triglycerides, rather than a decrease in synthesis. One candidate for this effect is a tumor lipid mobilizing factor, which stimulates lipolysis directly through a cyclic AMP-mediated process via interaction with a beta3-adrenergic receptor. Loss of skeletal muscle arises from both a depression in protein synthesis and an increase in protein degradation. The major proteolytic pathway involved in intracellular protein breakdown in cachectic muscle is the ATP-ubiquitin-dependent proteolytic pathway. Both PIF and tumor necrosis factor-alpha, but not other cytokines, can induce expression of the key regulatory components of this pathway. **Eicosapentaenoic acid**, found in oily fish, effectively attenuates protein degradation in cachectic muscle by inhibiting the increased proteasome expression and can stabilize body weight in cachectic cancer patients.

CT Adipose Tissue: DE, drug effects

Adipose Tissue: PP, physiopathology

Cachexia: DT, drug therapy

Cachexia: ET, etiology

*Cachexia: PP, physiopathology

Cytokines: PH, physiology

Dietary Supplements

Disease Progression

Eicosapentaenoic Acid: PD, pharmacology

Eicosapentaenoic Acid: TU, therapeutic use

Energy Metabolism: PH, physiology

Humans

Muscle, Skeletal: DE, drug effects

Muscle, Skeletal: PP, physiopathology

Neoplasms: CO, complications

*Neoplasms: PP, physiopathology

Weight Loss: DE, drug effects

RN 1553-41-9 (**Eicosapentaenoic Acid**)

CN 0 (Cytokines)

L68 ANSWER 2 OF 12 MEDLINE on STN

AN 2003591984 MEDLINE

DN PubMed ID: 14673061

TI **Eicosapentaenoic acid** as a targeted therapy for cancer cachexia.

AU Belda-Iniesta Cristobal; de Castro Carpeno Javier; Fresno Vara Juan Angel;
 Cejas Guerrero Paloma; Casado Saenz Enrique; Espinosa Arranz Enrique;
 Redondo Sanchez Andres; Feliu Battle Jaime; Gonzalez Baron Manuel

SO Journal of clinical oncology : official journal of the American Society of
 Clinical Oncology, (2003 Dec 15) Vol. 21, No. 24, pp. 4657-8;
 author reply 4658.
 Journal code: 8309333. ISSN: 0732-183X.

CM Comment on: J Clin Oncol. 2003 Jan 1;21(1):129-34. PubMed ID: 12506181

CY United States

DT Commentary
 Letter

LA English

FS Priority Journals

EM 200402

ED Entered STN: 16 Dec 2003
 Last Updated on STN: 14 Feb 2004
 Entered Medline: 13 Feb 2004

CT Animals
 Anorexia: ET, etiology
 *Anorexia: TH, therapy
 Cachexia: ET, etiology
 *Cachexia: TH, therapy
 *Dietary Supplements
 *Eicosanoic Acids: TU, therapeutic use
 *Fish Oils: TU, therapeutic use
 Humans
 *Neoplasms: CO, complications

CN 0 (Eicosanoic Acids); 0 (Fish Oils)

L68 ANSWER 3 OF 12 MEDLINE on STN

AN 2002741916 MEDLINE

DN PubMed ID: 12506181

TI Effect of fish oil on appetite and other symptoms in patients with
 advanced cancer and anorexia/cachexia: a double-blind,
 placebo-controlled study.

AU Bruera Eduardo; Strasser Florian; Palmer J Lynn; Willey Jie; Calder
 Kathryn; Amyotte Gail; Baracos Vickie

CS Department of Palliative Care and Rehabilitation Medicine, The University
 of Texas M.D. Anderson Cancer Center, Houston, TX 77030-0049, USA..
 ebruera@mail.mdanderson.org

SO Journal of clinical oncology : official journal of the American Society of
 Clinical Oncology, (2003 Jan 1) Vol. 21, No. 1, pp. 129-34.
 Journal code: 8309333. ISSN: 0732-183X.

CM Comment in: J Clin Oncol. 2003 Dec 15;21(24):4657-8; author reply 4658.
 PubMed ID: 14673061
 Comment in: J Clin Oncol. 2003 Sep 15;21(18):3545; author reply 3545-6.
 PubMed ID: 12972541

CY United States

DT (CLINICAL TRIAL)
 Journal; Article; (JOURNAL ARTICLE)
 (RANDOMIZED CONTROLLED TRIAL)

LA English

FS Priority Journals

EM 200301

ED Entered STN: 31 Dec 2002
 Last Updated on STN: 16 Jan 2003
 Entered Medline: 15 Jan 2003

AB PURPOSE: To determine whether high doses of fish oil, administered over 2
 weeks, improve symptoms in patients with advanced cancer and decreased
 weight and appetite. PATIENTS AND METHODS: Sixty patients were randomly

assigned to fish oil capsules or placebo. Appetite, tiredness, nausea, well-being, caloric intake, nutritional status, and function were prospectively assessed at days 1 and 14. RESULTS: The baseline weight loss was 16 +/- 11 and 16 +/- 8 kg in the fish oil (n = 30) and placebo (n = 30) group respectively, whereas the baseline appetite (0 mm = best and 10 mm = worst) was 58 +/- 24 mm and 67 +/- 19 mm, respectively (P = not significant). The mean daily dose was 10 +/- 4 (fish oil group) and 9 +/- 3 (placebo group) capsules, which provided 1.8 g of eicosapentaenoic acid and 1.2 g of docosahexaenoic acid in the fish oil group. No significant differences in symptomatic or nutritional parameters were found (P <.05), and there was no correlation between changes in different variables between days 1 and 14 and the fish oil doses. Finally, the majority of the patients were not able to swallow more than 10 fish oil capsules per day, mainly because of burping and aftertaste. CONCLUSION: Fish oil did not significantly influence appetite, tiredness, nausea, well-being, caloric intake, nutritional status, or function after 2 weeks compared with placebo in patients with advanced cancer and loss of both weight and appetite.

CT Check Tags: Female; Male
 Anorexia: ET, etiology
 *Anorexia: TH, therapy
 Cachexia: ET, etiology
 *Cachexia: TH, therapy
 *Dietary Supplements
 Double-Blind Method
 *Fish Oils: TU, therapeutic use
 Humans
 Middle Aged
 *Neoplasms: CO, complications
 Research Support, Non-U.S. Gov't
 Statistics, Nonparametric
 CN 0 (Fish Oils)

L68 ANSWER 4 OF 12 MEDLINE on STN
 AN 2002655005 MEDLINE
 DN PubMed ID: 12415256
 TI Cachexia in cancer patients.
 AU Tisdale Michael J
 CS Pharmaceutical Sciences Research Institute, Aston University, Birmingham
 B4 7ET, UK.. m.j.tisdale@aston.ac.uk
 SO Nature reviews. Cancer, (2002 Nov) Vol. 2, No. 11, pp. 862-71.
 Ref: 94
 Journal code: 101124168. ISSN: 1474-175X.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200212
 ED Entered STN: 5 Nov 2002
 Last Updated on STN: 18 Dec 2002
 Entered Medline: 13 Dec 2002
 CT Acute-Phase Proteins: ME, metabolism
 Adipose Tissue: ME, metabolism
 Animals
 Anorexia: CI, chemically induced
 Anorexia: ET, etiology
 Anorexia: ME, metabolism
 Body Composition
 *Cachexia

Cachexia: DT, drug therapy
 Cachexia: ET, etiology
 Cachexia: ME, metabolism
 Carrier Proteins: PH, physiology
 Comparative Study
 Cysteine Endopeptidases: ME, metabolism
 Cytokines: PH, physiology
Eicosapentaenoic Acid: TU, therapeutic use
 Energy Intake
 Energy Metabolism
 Fish Oils: TU, therapeutic use
 Humans
 Hypothalamus: PP, physiopathology
 Lipolysis
 Multienzyme Complexes: ME, metabolism
 Muscle Proteins: ME, metabolism
 Muscle, Skeletal: ME, metabolism
 Neoplasm Proteins: PH, physiology
 *Neoplasms: CO, complications
 Neoplasms: ME, metabolism
 Neuropeptides: PH, physiology
 Proteasome Endopeptidase Complex
 Rats
 Ubiquitin: ME, metabolism
 Weight Loss

RN 1553-41-9 (Eicosapentaenoic Acid)

CN 0 (Acute-Phase Proteins); 0 (Carrier Proteins); 0 (Cytokines); 0 (Fish
 Oils); 0 (Multienzyme Complexes); 0 (Muscle Proteins); 0 (Neoplasm
 Proteins); 0 (Neuropeptides); 0 (Ubiquitin); 0 (mitochondrial uncoupling
 protein 3); EC 3.4.22 (Cysteine Endopeptidases); EC 3.4.25.1 (Proteasome
 Endopeptidase Complex)

L68 ANSWER 5 OF 12 MEDLINE on STN

AN 2002011631 MEDLINE

DN PubMed ID: 11377146

TI Cancer **anorexia** and cachexia.

AU Tisdale M J

CS Pharmaceutical Sciences Research Institute, Aston University, Birmingham,
 United Kingdom.

SO Nutrition (Burbank, Los Angeles County, Calif.), (2001 May) Vol.
 17, No. 5, pp. 438-42. Ref: 80
 Journal code: 8802712. ISSN: 0899-9007.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LA English

FS Priority Journals

EM 200201

ED Entered STN: 21 Jan 2002

Last Updated on STN: 25 Jan 2002

Entered Medline: 3 Jan 2002

AB Patients with cancer cachexia experience a profound wasting of adipose
 tissue and lean body mass. **Anorexia**, although often present, is
 insufficient to account for tissue wasting because 1) cachexia involves
 massive depletion of skeletal muscle that does not occur during
anorexia, 2) nutritional supplementation cannot replenish the loss
 of lean body mass, 3) cachexia can occur without **anorexia**, and
 4) food intake might be normal for the lower weight of the cancer patient.
Anorexia can arise from 1) decreased taste and smell of food, 2)
 early satiety, 3) dysfunctional hypothalamic membrane adenylate cyclase,

4) increased brain tryptophan, and 5) cytokine production. Appetite stimulants such as cyproheptadine, medroxyprogesterone acetate, and megestrol acetate do not significantly improve lean body mass. Tumor products might be more important in the development of cachexia. Cachectic patients excrete in their urine a lipid-mobilizing factor that directly stimulates lipolysis in a cyclic AMP-dependent manner and increases energy expenditure. Loss of skeletal muscle in cachexia is caused by upregulation of the ubiquitin-proteasome catabolic pathway. Cachexia-inducing tumors elaborate a sulfated glycoprotein, which directly initiates protein catabolism in skeletal muscle. The action of this proteolysis-inducing factor is attenuated by the polyunsaturated fatty acid **eicosapentaenoic acid**, which is also effective in preventing loss of skeletal muscle in cancer patients. Antagonists of tumor catabolic factors will provide important new agents in the treatment of cancer cachexia.

CT *Anorexia: ET, etiology

Anorexia: ME, metabolism

Anorexia: TH, therapy

Appetite Stimulants: TU, therapeutic use

Blood Proteins: ME, metabolism

*Cachexia: ET, etiology

Cachexia: ME, metabolism

Cachexia: TH, therapy

Eicosanoic Acids: TU, therapeutic use

Humans

Lipid Metabolism

*Muscle, Skeletal: ME, metabolism

Neoplasms: ME, metabolism

*Neoplasms: PP, physiopathology

Peptides: ME, metabolism

Proteins: ME, metabolism

Research Support, Non-U.S. Gov't

CN 0 (Appetite Stimulants); 0 (Blood Proteins); 0 (Eicosanoic Acids); 0 (Peptides); 0 (Proteins); 0 (lipid mobilizing substance); 0 (proteolysis-inducing peptide)

L68 ANSWER 6 OF 12 MEDLINE on STN

AN 2001667143 MEDLINE

DN PubMed ID: 11712791

TI Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management.

AU Gadducci A; Cosio S; Fanucchi A; Genazzani A R

CS Department of Procreative Medicine, University of Pisa, Italy..

a.gadducci@obgyn.med.unipi.it

SO Anticancer research, (2001 Jul-Aug) Vol. 21, No. 4B, pp. 2941-7.

Ref: 92

Journal code: 8102988. ISSN: 0250-7005.

CY Greece

DT Journal; Article; (JOURNAL ARTICLE)

General Review; (REVIEW)

LA English

FS Priority Journals

EM 200112

ED Entered STN: 20 Nov 2001

Last Updated on STN: 23 Jan 2002

Entered Medline: 10 Dec 2001

AB In ovarian cancer patients the poor nutritional status and cachexia are caused by the metabolic effects of the enlarging tumor masses and bowel obstruction. These patients may have a high resting energy expenditure due to increase in Cori cycle activity, glucose and triglyceride-fatty

acid cycling and gluconeogenesis. Biochemical mediators of cachexia include cytokines, such as tumor necrosis factor and interleukin-6, and tumor-produced catabolic factors, such as lipid-mobilizing factor, proteolysis-inducing factor, and anemia-inducing factor. Mechanisms involved in the pathogenesis of obstruction may include extrinsic occlusion of the bowel due to pelvic, mesenteric omental masses, or intestinal motility disorders due to infiltration of the mesentery or bowel muscle and nerves. The relief of malnutrition and cachexia may be attempted through nutritional support, pharmacological approach (megestrol acetate, cyclooxygenase inhibitors) and palliative treatment of bowel obstruction. Very few agents have been demonstrated to have true anticachectic activity, so future research should be addressed to the identification of drugs able to block the activity of tumor-produced catabolic factors. The decision regarding optimum management of bowel obstruction should be individualized. Krebs' and Goplerud's score (based on age, nutritional status, tumor status, ascites, previous chemotherapy and irradiation) seems to offer reliable eligibility criteria for those patients who can benefit from surgery.

CT Check Tags: Female
 Adrenergic beta-Antagonists: PD, pharmacology
 Anaerobiosis
 Animals
 Anorexia: ET, etiology
 Ascites: ME, metabolism
 CHO Cells
 *Cachexia: ET, etiology
 Cachexia: PP, physiopathology
 Cachexia: TH, therapy
 Carbohydrate Metabolism
 Cricetinae
 Cricetulus
 Cyclooxygenase Inhibitors: TU, therapeutic use
 Cytokines: PH, physiology
 Eicosapentaenoic Acid: TU, therapeutic use
 Energy Metabolism: DE, drug effects
 Fatty Acids: ME, metabolism
 Floxuridine: TU, therapeutic use
 Glycolysis
 Humans
 Interleukin-6: GE, genetics
 Interleukin-6: PH, physiology
 Intestinal Obstruction: ET, etiology
 Intestinal Obstruction: SU, surgery
 Intestinal Obstruction: TH, therapy
 Intubation, Gastrointestinal
 Linoleic Acid: ME, metabolism
 Lipolysis: DE, drug effects
 Lipoprotein Lipase: AI, antagonists & inhibitors
 Megestrol Acetate: PD, pharmacology
 Mice
 Mice, Nude
 Nausea: ET, etiology
 *Nutrition Disorders: ET, etiology
 Nutrition Disorders: PP, physiopathology
 Nutrition Disorders: TH, therapy
 *Ovarian Neoplasms: CO, complications
 Ovarian Neoplasms: ME, metabolism
 Palliative Care
 Parenteral Nutrition, Total: AE, adverse effects
 Proteins: ME, metabolism

Quality of Life
 Transfection
 Tumor Necrosis Factor-alpha: GE, genetics
 Tumor Necrosis Factor-alpha: PH, physiology
 RN 1553-41-9 (**Eicosapentaenoic Acid**); 2197-37-7 (Linoleic Acid);
 3094-09-5 (doxifluridine); 50-91-9 (Floxuridine); 51154-23-5 (Megestrol
 Acetate)
 CN 0 (Adrenergic beta-Antagonists); 0 (Cyclooxygenase Inhibitors); 0
 (Cytokines); 0 (Fatty Acids); 0 (Interleukin-6); 0 (Proteins); 0 (Tumor
 Necrosis Factor-alpha); EC 3.1.1.34 (Lipoprotein Lipase)
 L68 ANSWER 7 OF 12 MEDLINE on STN
 AN 2001537493 MEDLINE
 DN PubMed ID: 11346935
 TI Current management of cancer-associated **anorexia** and weight
 loss.
 AU Jatoi A Jr; Loprinzi C L
 CS Division of Medical Oncology Mayo Clinic, Rochester, Minnesota, USA.
 Comprehensive Cancer Center, Northwestern University, Chicago, Illinois,
 USA.. w-small@northwestern.edu
 SO Oncology (Williston Park, N.Y.), (2001 Apr) Vol. 15, No. 4, pp.
 497-502, 508; discussion 508-10. Ref: 44
 Journal code: 8712059. ISSN: 0890-9091.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200110
 ED Entered STN: 8 Oct 2001
 Last Updated on STN: 8 Oct 2001
 Entered Medline: 4 Oct 2001
 AB Loss of appetite and weight predict a poor prognosis for cancer patients.
 Although caloric supplementation might benefit subgroups of
 patients--specifically, perioperative, severely malnourished cancer
 patients, stem cell and bone marrow transplant patients and head and neck
 cancer patients--its use remains controversial and is not recommended for
 the majority of patients with cancer-associated weight loss. Most
 patients with advanced cancer, **anorexia**, and/or weight loss do
 not appear to benefit from nutritional supplementation. Instead,
 discussions with patients and families about realistic eating goals and,
 at timearmacologic interventions with progestational agents or
 corticosteroids--both of which are aimed at palliating **anorexia**
 --provide clinical benefit. Other pharmacologic interventions such as
eicosapentaenoic acid, thalidomide (Thalomid), adenosine
 triphosphate and nonsteroidal anti-inflammatory agents focus on the fact
 that cancer-associated weight loss is an entity distinct from simple
 starvation. These interventions promise to replenish lean tissue but
 require further investigation before they can be recommended as standard
 clinical practice.
 CT Algorithms
 Anorexia: ET, etiology
 ***Anorexia: TH, therapy**
 Humans
 *Neoplasms: CO, complications
 Nutritional Support: MT, methods
 *Weight Loss: DE, drug effects
 Weight Loss: PH, physiology
 L68 ANSWER 8 OF 12 MEDLINE on STN

AN 2001299849 MEDLINE
 DN PubMed ID: 11054609
 TI Metabolic abnormalities in cachexia and **anorexia**.
 AU Tisdale M J
 CS Pharmaceutical Sciences Research Institute, Aston University, Birmingham, UK.. m.j.tisdale@aston.ac.uk
 SO Nutrition (Burbank, Los Angeles County, Calif.), (2000 Oct) Vol. 16, No. 10, pp. 1013-4. Ref: 34
 Journal code: 8802712. ISSN: 0899-9007.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 200105
 ED Entered STN: 4 Jun 2001
 Last Updated on STN: 4 Jun 2001
 Entered Medline: 31 May 2001
 AB An increased glucose requirement by many solid tumors produces an increased metabolic demand on the liver, resulting in an increased energy expenditure. In addition, several cytokines and tumor catabolic products have been suggested as being responsible for the depletion of adipose tissue and skeletal-muscle mass in cachexia. A sulphated glycoprotein of molecular mass 24 kDa, produced by cachexia-inducing tumors and present in the urine of cancer patients actively losing weight, has been shown to be capable of inducing direct muscle catabolism in vitro and a state of cachexia in vivo, with specific loss of the non-fat carcass mass. In vitro studies have shown the bioactivity of this proteolysis-inducing factor to be attenuated by the polyunsaturated fatty acid, **eicosapentaenoic acid**. Preliminary clinical studies have shown that **eicosapentaenoic acid** stabilizes body weight and protein and fat reserves in patients with pancreatic carcinoma. Further trials are required to confirm the efficacy of **eicosapentaenoic acid** and to determine the anticachectic activity in other types of cancer.
 CT ***Anorexia: ME, metabolism**
 *Cachexia: ME, metabolism
 *Carbohydrate Metabolism
 Eicosanoic Acids: TU, therapeutic use
 Humans
 *Lipid Metabolism
 *Proteins: ME, metabolism
 CN 0 (Eicosanoic Acids); 0 (Proteins)
 L68 ANSWER 9 OF 12 MEDLINE on STN
 AN 1999115860 MEDLINE
 DN PubMed ID: 9915907
 TI Wasting in cancer.
 AU Tisdale M J
 CS Pharmaceutical Sciences Institute, Aston University, Birmingham B4 7ET, United Kingdom.
 SO The Journal of nutrition, (1999 Jan) Vol. 129, No. 1S Suppl, pp. 243S-246S. Ref: 46
 Journal code: 0404243. ISSN: 0022-3166.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals; AIDS
 EM 199902

ED Entered STN: 11 Mar 1999
 Last Updated on STN: 11 Mar 1999
 Entered Medline: 22 Feb 1999

AB Progressive weight loss is a common feature of many types of cancer and is responsible not only for a poor quality of life and poor response to chemotherapy, but also a shorter survival time than is found in patients with comparable tumors without weight loss. Although **anorexia** is common, a decreased food intake alone is unable to account for the changes in body composition seen in cancer patients, and increasing nutrient intake is unable to reverse the wasting syndrome. Although energy expenditure is increased in some patients, cachexia can occur even with a normal energy expenditure. Various factors have been investigated as mediators of tissue wasting in cachexia. These include cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interferon-gamma (IFN-gamma) and leukemia inhibitory factor (LIF), as well as tumor-derived factors such as lipid mobilizing factor (LMF) and protein mobilizing factor (PMF), which can directly mobilize fatty acids and amino acids from adipose tissue and skeletal muscle respectively. Induction of lipolysis by the cytokines is thought to result from an inhibition of lipoprotein lipase (LPL), although clinical studies provide no evidence for an inhibition of LPL in the adipose tissue of cancer patients. Instead there is an increased expression of hormone sensitive lipase, the enzyme activated by LMF. Protein degradation in cachexia is associated with an increased activity of the ATP-ubiquitin-proteasome pathway. The biological activity of both the LMF and PMF was shown to be attenuated by **eicosapentaenoic acid** (EPA). Clinical studies show that this polyunsaturated fatty acid is able to stabilize the rate of weight loss and adipose tissue and muscle mass in cachectic patients with unresectable pancreatic cancer. Knowledge of the mechanism of cancer cachexia should lead to the development of new therapeutic agents.

CT **Anorexia: ME, metabolism**
 Energy Metabolism: PH, physiology
 *HIV Wasting Syndrome: ME, metabolism
 HIV Wasting Syndrome: PA, pathology
 Humans
 Lipid Metabolism
 Muscles: ME, metabolism
 Weight Loss: PH, physiology

L68 ANSWER 10 OF 12 MEDLINE on STN
 AN 1998052510 MEDLINE
 DN PubMed ID: 9392617
 TI Biology of cachexia.
 AU Tisdale M J
 SO Journal of the National Cancer Institute, (1997 Dec 3) Vol. 89, No. 23, pp. 1763-73. Ref: 138
 Journal code: 7503089. ISSN: 0027-8874.
 CM Comment in: J Natl Cancer Inst. 1998 Apr 15;90(8):628. PubMed ID: 9554447
 Comment in: J Natl Cancer Inst. 1999 Jun 16;91(12):1077; author reply 1077-8. PubMed ID: 10379972
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 LA English
 FS Priority Journals
 EM 199712
 ED Entered STN: 9 Jan 1998
 Last Updated on STN: 3 Mar 2000
 Entered Medline: 18 Dec 1997

AB About half of all cancer patients show a syndrome of cachexia,

characterized by loss of adipose tissue and skeletal muscle mass. Such patients have a decreased survival time, compared with the survival time among patients without weight loss, and loss of total body protein leads to substantial impairment of respiratory muscle function. These changes cannot be fully explained by the accompanying **anorexia**, and nutritional supplementation alone is unable to reverse the wasting process. Despite a falling caloric intake, patients with cachexia frequently show an elevated resting energy expenditure as a result of increases in Cori cycle (i.e., catalytic conversion of lactic acid to glucose) activity, glucose and triglyceride-fatty acid cycling, and gluconeogenesis. A number of cytokines, including tumor necrosis factor- α , interleukins 1 and 6, interferon gamma, and leukemia-inhibitory factor, have been proposed as mediators of the cachectic process. However, the results of a number of clinical and laboratory studies suggest that the action of the cytokines alone is unable to explain the complex mechanism of wasting in cancer cachexia. In addition, cachexia has been observed in some xenograft models even without a cytokine involvement, suggesting that other factors may be involved. These probably include catabolic factors, which act directly on skeletal muscle and adipose tissue and the presence of which has been associated with the clinical development of cachexia. A polyunsaturated fatty acid, **eicosapentaenoic acid**, attenuates the action of such catabolic factors and has been shown to stabilize the process of wasting and resting energy expenditure in patients with pancreatic cancer. Such a pharmacologic approach may provide new insights into the treatment of cachexia.

CT *Cachexia: ET, etiology
 *Cachexia: ME, metabolism
 Cachexia: TH, therapy
 Carbohydrate Metabolism
 Growth Inhibitors: ME, metabolism
 Humans
 Interferon Type II: ME, metabolism
 *Interleukin-6
 Interleukins: ME, metabolism
 Lipid Metabolism
 Lymphokines: ME, metabolism
 *Neoplasms: CO, complications
 *Neoplasms: ME, metabolism
 Peptides: ME, metabolism
 Proteins: ME, metabolism
 Tumor Necrosis Factor- α : ME, metabolism
 RN 82115-62-6 (Interferon Type II)
 CN 0 (Growth Inhibitors); 0 (Interleukin-6); 0 (Interleukins); 0 (Lymphokines); 0 (Peptides); 0 (Proteins); 0 (Tumor Necrosis Factor- α); 0 (leukemia inhibitory factor); 0 (lipid mobilizing substance)

L68 ANSWER 11 OF 12 MEDLINE on STN
 AN 97352489 MEDLINE
 DN PubMed ID: 9208884
 TI The cancer cachexia syndrome.
 AU Puccio M; Nathanson L
 CS Winthrop University Hospital, Mineola, NY, USA.
 SO Seminars in oncology, (1997 Jun) Vol. 24, No. 3, pp. 277-87.
 Ref: 60
 Journal code: 0420432. ISSN: 0093-7754.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)

LA English
 FS Priority Journals
 EM 199707
 ED Entered STN: 5 Aug 1997
 Last Updated on STN: 5 Aug 1997
 Entered Medline: 23 Jul 1997

AB The cancer cachexia syndrome is clinically characterized by **anorexia**, wasting, weight loss, weakness, fatigue, poor performance status, and impaired immune function, which are unresolved by forced caloric intake. Diminished nutritional intake, maladaptive metabolic processes, and increased metabolic expenditure all play roles in the development of this syndrome. Multiple mediators of both tumor and host cell origin are mechanistic in its etiology. Treatment is not entirely satisfactory and should be directed toward improvement in the quality of life of the patient and should often include nutritional counseling. It should take into consideration both disease and treatment related factors as well as the cachexia syndrome itself. Use of progestogens (megesterol acetate, medroxyprogesterone), corticosteroids (decadron, prednisone), metoclopramide, tetrahydrocannabinol (dronabinol), and possibly anabolic steroids (nandrolone decanoate, oxandrolone), melatonin, and **eicosapentaenoic acid**, may yield therapeutic benefit.

CT **Anorexia: ET, etiology**
 Appetite Stimulants
 Cachexia: DI, diagnosis
 *Cachexia: ET, etiology
 Cachexia: PP, physiopathology
 Cachexia: TH, therapy
 Humans
 *Neoplasms: CO, complications
 Nutritional Support
 Syndrome

CN 0 (Appetite Stimulants)

L68 ANSWER 12 OF 12 MEDLINE on STN
 AN 93257719 MEDLINE
 DN PubMed ID: 8490191
 TI Cancer cachexia.
 AU Tisdale M J
 CS Pharmaceutical Sciences Institute, Aston University, Birmingham, UK.
 SO Anti-cancer drugs, (1993 Apr) Vol. 4, No. 2, pp. 115-25. Ref: 102
 Journal code: 9100823. ISSN: 0959-4973.

CY ENGLAND: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)

LA English
 FS Priority Journals
 EM 199306
 ED Entered STN: 25 Jun 1993
 Last Updated on STN: 25 Jun 1993
 Entered Medline: 16 Jun 1993

AB Cachexia is a common problem in the clinical management of cancer patients, particularly those with solid tumors. Cachexia is most obviously manifested as weight loss with massive depletion of both adipose tissue and muscle mass, and death is probably due to loss of lean body tissue. Not only is the survival time shorter in patients with cachexia, but the frequency of response to chemotherapy is also significantly reduced. Although **anorexia** frequently accompanies cachexia, attempts to halt or reverse cachexia by nutritional repletion have not

been successful. This suggests that cachexia is due to metabolic abnormalities produced by the tumor in addition to the underlying **anorexia**. In some patients weight loss is associated with an increased relative energy expenditure possibly through an elevated adrenergic state. Several factors have been postulated as mediators of cancer cachexia and can be divided into two groups. (i) Materials with hormone-like characteristics which result in direct catabolism of host tissues. (ii) Cytokines which cause alterations in host metabolism indirectly. Included in group (i) are the conventional catabolic hormones and a lipid mobilizing factor (LMF) produced by tumors, which causes direct breakdown of adipose tissue. Included in group (ii) are tumor necrosis factor-alpha, interleukin-6, interferon-gamma and leukaemia inhibitory factor. The materials appear to influence adipose tissue indirectly through an inhibition of lipoprotein lipase. Reversal of cachexia has been achieved by two groups of agents. (i) Those stimulating food intake, e.g. megestrol acetate. (ii) Those directly inhibiting the LMF, e.g. **eicosapentaenoic acid**. While agents in group (i) can cause tumor growth stimulation, those in group (ii) act as tumor growth inhibitors. This latter results suggests that the products of catabolism of host tissues may be important for tumor growth and provides a new avenue for chemotherapeutic intervention.

CT Animals

*Cachexia: ET, etiology

Cachexia: PP, physiopathology

Cachexia: TH, therapy

Humans

*Neoplasms: CO, complications

Research Support, Non-U.S. Gov't

=> => fil wpix

FILE 'WPIX' ENTERED AT 11:49:37 ON 10 MAY 2006

COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE LAST UPDATED: 5 MAY 2006 <20060505/UP>

MOST RECENT DERWENT UPDATE: 200629 <200629/DW>

DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:

http://www.stn-international.de/training_center/patents/stn_guide.pdf <

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://scientific.thomson.com/support/patents/coverage/latestupdates/>

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html and
<http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf> <<<

>>> UPCOMING NEW DWPI: EFFECTS ON SCRIPT RUNS - SEE NEWS MESSAGE <<<
'BI ABEX' IS DEFAULT SEARCH FIELD FOR 'WPIX' FILE

=> d 190 all abeq tech abex dcn tot

L90 ANSWER 1 OF 3 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN 2005-497692 [50] WPIX

DNC C2005-151360

TI Composition, useful for controlling body weight, comprises (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid and (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid.

DC B05 D13

IN BRYHN, M; KOPECKY, J

PA (PRON-N) PRONOVA BIO CARE AS

CYC 108

PI WO 2005060954 A1 20050707 (200550)* EN 61 A61K031-202

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IS IT
KE LS LT LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG
ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE
DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG
KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ
OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG
US UZ VC VN YU ZA ZM ZW

ADT WO 2005060954 A1 WO 2004-IB4178 20041217

PRAI US 2003-530644P 20031219; SE 2003-3513 20031219

IC ICM A61K031-202
ICS A23L001-307; A61K031-557; **A61P003-04**

AB WO2005060954 A UPAB: 20050805

NOVELTY - In the production of a medicinal product for controlling body weight, for preventing body weight gain and for treatment and/or prevention of obesity or an overweight condition, a fatty acid composition comprising at least one of (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA) and/or (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA) or their derivatives is used.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a dietary product containing the fatty acid composition, for non-medical treatment and/or prevention of obesity, an overweight condition and/or for supporting and controlling body weight reduction and/or for prevention of body weight gain.

ACTIVITY - Anorectic.

The effects of an omega-3 fatty acid composition containing EPA and DHA on the body weight were studied. A mixture containing EPA (approx. 20%) and DHA (50%) was used. Groups (n=7) of adult male mice (C57BL/6J mouse) fed standard feeding diet (4% fat), were randomly assigned one of four different types of semisynthetic high-fat (20% fat) diets where the fat component was: Group (I) Lard (L), Group (II) Lard plus EPAX2050TG (L+FO: EPAX 2050TG formed 44 weight/weight% of total lipid content), Group (III) Flaxseed oil (Ln) (18:3n-3 forms 50% of total lipids, Ln) and Group (IV) Flaxseed plus EPAX2050TG (Ln+FO; EPAX2050TG) (where FO is various EPA and DHA concentrates (for instance EPAX high in DHA versus EPAX high in EPA) used in these studies). The animals were fed the different diets during 1 month. After the study, the total body weight was reduced in Group (II) (L+FO) versus Group (I) (L); and Group (IV) (Ln+FO) versus Group (III) (Ln), and the difference was statistically significant in Group (IV) versus (III). The body weights of mice before treatment were similar in all the groups. The mice's given flaxseed oil plus EPAX2050TG had decreased by 10% in body weight compared to the mice's only given flaxseed oil. The study demonstrated that treatment with a fatty acid composition containing EPA and DHA leads to weight reduction.

MECHANISM OF ACTION - None given.

USE - The composition is useful for controlling body weight reduction, for preventing body weight gain and for treatment and/or prevention of obesity or an overweight condition. It is also useful for the production of a food stuff or food supplement in form of a flavored gelatine capsule for controlling and supporting body weight reduction

and/or for prevention of body weight gain; and as a dietary product (e.g. weight-watching product or slimming product). Also for supplementing a dietary product (all claimed).

ADVANTAGE - The composition reduces intake of calories in a human or animal. The composition has stronger body weight lowering effect.

Dwg.0/6

FS CPI

FA AB; DCN

MC CPI: B10-C04E; **B14-E12**; D03-H01G; D03-H01T2; D03-H01T3

TECH UPTX: 20050805

TECHNOLOGY FOCUS - BIOLOGY - Preferred Components: At least one of EPA and DHA is obtained from at least one of vegetable, microbial and/or animal origin. At least a part of the EPA and/or DHA is produced from marine oil (preferably fish oil).

TECHNOLOGY FOCUS - FOOD - Preferred Composition: When the fatty acid composition is a liquid or an emulsion, then it is in a form of food stuff or food supplement is administered as a beverage. The main active ingredient is DHA. The intake of the composition in the form of dietary product is combined with a reduced intake of calories for a human and/or together with physical activity. The dietary product is a bar, snack or beverage. The fatty acid composition is in liquid form or as an emulsion, for incorporation in a supplement product.

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: The weight ratio of EPA:DHA in the fatty acid composition is 1:greater than or equal to 1 (preferably 1:1 - 1:8, 1:1 - 1:6). In the composition, the fatty acid is provided in at least one of esterified form, ethyl ester form, salt form and/or free acid form. The fatty acid composition is comprised of a combination of EPA and DHA in triglyceride form.

ABEX UPTX: 20050805

ADMINISTRATION - The daily dosage of the fatty acid composition is 1 - 15 (preferably 2 - 6) g for a human, and is administered in a daily dosage that corresponds to at least 10 (preferably 10 - 40)% of the total lipid content of a daily diet for a human or animal. The fatty acid composition is administered orally to human or animal (all claimed). The fatty acid composition may also be administered intravenously, subcutaneously, intramuscularly, intranasally, rectally, vaginally or topically.

M2 *01* DCN: **R04470-M; R04470-U; R04470-K;**

R13712-M; R13712-U; R13712-K

M2 *02* DCN: R04471-M; R04471-U; R04471-K; R13713-M; R13713-U; R13713-K

L90 ANSWER 2 OF 3 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN

AN **2004-269885** [25] WPIX

DNC C2004-105011

TI Use of **eicosapentaenoic acid** in the manufacture of a medicament for the treatment of **anorexia nervosa**, **bulimia** and related clinical syndromes.

DC B05

IN AYTON, A; HORROBIN, D F; DAVID, F H

PA (LAXD-N) LAXDALE LTD; (AMAR-N) AMARIN NEUROSCIENCE LTD

CYC 108

PI WO 2004024136 A1 20040325 (200425)* EN 31 A61K031-202

RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS
LU MC MW MZ NL OA PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG
PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ
VC VN YU ZA ZM ZW

AU 2003269138 A1 20040430 (200462) A61K031-202

NO 2005001847 A 20050415 (200534) A61K031-202
 EP 1556028 A1 20050727 (200549) EN A61K031-202
 R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LT LU LV
 MC MK NL PT RO SE SI SK TR
 ZA 2005002161 A 20051026 (200577) 34 A61K000-00
 TW 2004010682 A 20040701 (200580) A61K031-202
 JP 2006503031 W 20060126 (200609) 19 A61K031-185
 CN 1694694 A 20051109 (200618) A61K031-202
 BR 2003017857 A 20051206 (200624) A61K031-202
 ADT WO 2004024136 A1 WO 2003-GB3985 20030916; AU 2003269138 A1 AU 2003-269138
 20030916; NO 2005001847 A WO 2003-GB3985 20030916, NO 2005-1847 20050415;
 EP 1556028 A1 EP 2003-750919 20030916, WO 2003-GB3985 20030916; ZA
 2005002161 A ZA 2005-2161 20050315; TW 2004010682 A TW 2003-125483
 20030916; JP 2006503031 W WO 2003-GB3985 20030916, JP 2004-535695
 20030916; CN 1694694 A CN 2003-825169 20030916; BR 2003017857 A BR
 2003-17857 20030916, WO 2003-GB3985 20030916
 FDT AU 2003269138 A1 Based on WO 2004024136; EP 1556028 A1 Based on WO
 2004024136; JP 2006503031 W Based on WO 2004024136; BR 2003017857 A Based
 on WO 2004024136
 PRAI GB 2002-21480 20020916
 IC ICM A61K000-00; A61K031-185; A61K031-202
 ICS A61K031-201; A61K031-21; A61K031-231; A61K031-232; A61P003-00;
 A61P003-04; A61P025-00
 AB WO2004024136 A UPAB: 20040418
 NOVELTY - In the manufacture of a medicament for the treatment of
anorexia nervosa, bulimia and related clinical
 syndromes, **eicosapentaenoic acid (EPA)** is used.
 ACTIVITY - Anabolic; Eating-Disorder-Gen.; Antiemetic.
 A 15-year-old patient having 7.4-month history of dieting and eating
 difficulties had started with dietary restrictions and excessive exercise
 and proceeded to laxative abuse. Two months prior to being first seen she
 had stopped taking all solid food. She had lost 8 kg since stopping solid
 food, stopped menstruation and began to grow fine, downy lanugo hair over
 her body (common in **anorexia nervosa (AN)**). She was
 treated with a standard AN regime. This was ineffective and over the next
 two months she lost around 7 kg, which necessitated her admission to
 hospital. At this point she was extremely distressed and unable or
 unwilling to maintain a conversation. Her heart rate was very slow and her
 blood glucose was low, both signs of starvation. Over the following ten
 days she lost a further 5 kg in weight, to 42 kg. Her doctors believed
 that her life was in danger. She was treated with ethyl-
eicosapentaenoate (E-EPA) (1 g/day). This transformed her response
 to treatment. Over the following weeks she began to eat normally and
 within 12 weeks she was back to 57 kg. Her mood and cognitive functions
 improved and she became normally communicative. Instead of being obsessed
 by weight and food to the exclusion of everything else, she became
 interested in all aspects of her life and her future. Her weight was
 63/55/45/57/63 at pre-illness/1st doctor visit/hospitalization/dosing with
 E-EPA/3 months after discharge.
 MECHANISM OF ACTION - None given.
 USE - In the manufacture of a medicament for the treatment of
anorexia nervosa, bulimia and related clinical
 syndromes (claimed) e.g. vomiting disorders.
 ADVANTAGE - The **eicosapentaenoic acid** provides an
 effective treatment for **anorexia nervosa**.
 Dwg.0/5
 FS CPI
 FA AB; DCN
 MC CPI: B05-B01P; B10-C04E; B10-D03; B10-E04C; B10-E04D; B10-G02; B14-E05;
 B14-E11

TECH UPTX: 20040418
 TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Drug: The EPA is taken from natural EPA-containing oil; in the form of the free acid, salt, mono-, di- or tri-glycerides, phospholipid, amide, ester or any other biologically compatible derivative (preferably triglycerides or ethyl ester, especially ethyl ester); is 70, preferably 95% pure; and contains less than 10 (preferably 5)% in aggregate and less than 3 (preferably 2)% individually of docosaheptaenoic acid, linoleic acid or arachidonic acid.

ABEX UPTX: 20040418
 ADMINISTRATION - EPA is administered in a dosage of 50 mg - 20 g/day (preferably 300 mg - 3 g/day) orally by adding to a nutritional supplement. EPA is also administered parenterally, intramuscularly, intravenously or by enteral tube (all claimed).
 M1 *04* DCN: RA01PM-K; RA01PM-T; RA01PM-U
 M2 *01* DCN: R04470-K; R04470-T; R04470-U;
 R13712-K; R13712-T; R13712-U
 M2 *02* DCN: R15961-K; R15961-T; R15961-U
 M2 *03* DCN: 0127-37401-K; 0127-37401-T; 0127-37401-U

L90 ANSWER 3 OF 3 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
 AN 1997-011834 [01] WPIX
 CR 2001-183074 [18]; 2001-191564 [19]; 2002-025885 [03]; 2002-443183 [47];
 2002-690385 [74]; 2004-675631 [66]
 DNC C1997-003218
 TI Compsn. to slow gastrointestinal transit of nutrients and bio-active(s) -
 to improve absorption, using active lipid, useful in treating diarrhoea,
 dumping syndrome, **anorexia**, post-surgery, etc..
 DC B05
 IN LIN, H C
 PA (CEDA-N) CEDARS SINAI MEDICAL CENT
 CYC 71
 PI WO 9636330 A2 19961121 (199701)* EN 57 A61K031-20
 RW: AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD
 SE SZ UG
 W: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS
 JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
 RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN
 AU 9658629 A 19961129 (199712) A61K031-20
 EP 827402 A2 19980311 (199814) EN A61K031-20
 R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 BR 9608795 A 19990217 (199914) A61K031-20
 JP 11505258 W 19990518 (199930) 60 A61K047-14
 US 5977175 A 19991102 (199953) A61K031-20
 MX 9708858 A1 19980801 (200014) A61K031-20
 KR 99014865 A 19990225 (200018) A61K031-20
 AU 722133 B 20000720 (200040) A61K031-20
 MX 205865 B 20020107 (200307) A61K031-20
 ADT WO 9636330 A2 WO 1996-US7165 19960516; AU 9658629 A AU 1996-58629
 19960516; EP 827402 A2 EP 1996-920275 19960516, WO 1996-US7165 19960516;
 BR 9608795 A BR 1996-8795 19960516, WO 1996-US7165 19960516; JP 11505258 W
 JP 1996-535091 19960516, WO 1996-US7165 19960516; US 5977175 A Cont of US
 1995-442843 19950517, US 1997-832307 19970403; MX 9708858 A1 MX 1997-8858
 19971117; KR 99014865 A WO 1996-US7165 19960516, KR 1997-708210 19971117;
 AU 722133 B AU 1996-58629 19960516; MX 205865 B MX 1997-8858 19971117
 FDT AU 9658629 A Based on WO 9636330; EP 827402 A2 Based on WO 9636330; BR
 9608795 A Based on WO 9636330; JP 11505258 W Based on WO 9636330; KR
 99014865 A Based on WO 9636330; AU 722133 B Previous Publ. AU 9658629,
 Based on WO 9636330
 PRAI US 1995-442843 19950517; US 1997-832307 19970403
 IC ICM A61K031-20; A61K047-14

AB WO 9636330 A UPAB: 20050218
 Method for prolonging residence time of a substance in the small intestine, to allow absorption to occur, by admin. of an active lipid, is new.

USE - The method is used for enhancing the digestion and absorption of nutrients, and enhancing the absorption and bioavailability of pharmacologically active agents. Maximisation of nutrient and vitamin absorption is important after gastric, pancreatic, and/or intestinal surgery, in malnutrition, or in a range of disorders, including dumping syndrome, diarrhoea from a number of causes, steatorrhoea, asthenia, inflammatory bowel disease, peptide or endocrine tumours, cirrhosis, chronic alcohol dependence **anorexia**, bulaemia, endocrinopathies, and other enteropathies.

Dwg.0/2

FS CPI
 FA AB; DCN
 MC CPI: B04-B01B; B10-C04E; **B14-E11**
 M2 *01* DCN: 9701-33201-M; 9701-33201-U
 M2 *02* DCN: R03769-M; R03769-U
 M2 *03* DCN: R04038-M; R04038-U
 M2 *04* DCN: R03770-M; R03770-U
 M2 *05* DCN: R22533-M; R22533-U
 M2 *06* DCN: R01226-M; R01226-U
 M2 *07* DCN: R04471-M; R04471-U
 M2 *08* DCN: **R04470-M; R04470-U**
 M2 *09* DCN: R22531-M; R22531-U
 M2 *10* DCN: R18178-M; R18178-U
 M2 *11* DCN: R07145-M; R07145-U
 M2 *12* DCN: R01147-M; R01147-U
 M2 *13* DCN: R00206-M; R00206-U
 M2 *14* DCN: R01269-M; R01269-U
 M2 *15* DCN: R01356-M; R01356-U
 M2 *16* DCN: R21538-M; R21538-U
 M2 *17* DCN: R00954-M; R00954-U
 M2 *18* DCN: R00121-M; R00121-U
 M2 *19* DCN: R04540-M; R04540-U
 M2 *20* DCN: R00122-M; R00122-U
 M2 *21* DCN: R00758-M

=> e r04470+all/dcn

E1 647 --> R04470/DCN

E2 UF EICOSAPENTAENOIC ACID, 5,8,11,14,17-/DCN

***** END *****

=> e r13712+all/dcn

E1 429 --> R13712/DCN

E2 UF 5,8,11,14,17-EICOSAPENTAENOIC ACID-SALTS (GEN)/DCN

***** END *****

=> e r15961+all/dcn

E1 50 --> R15961/DCN

E2 UF EICOSAPENTAENOIC ETHYL ESTER/DCN

***** END *****

=> d his

(FILE 'HOME' ENTERED AT 10:51:31 ON 10 MAY 2006)

SET COST OFF

FILE 'HCAPLUS' ENTERED AT 10:51:37 ON 10 MAY 2006

L1 586 S E5,E8,E12-E16
 E HORROBIN/AU
 L2 2 S E4
 E AYTON/AU
 L3 29 S E3-E6,E13
 E CLARKSON S/AU
 L4 8204 S EICOSAPENTAENOIC ACID OR EICOSAPENTAENOATE

FILE 'REGISTRY' ENTERED AT 10:53:31 ON 10 MAY 2006

L5 1 S 10417-94-4
 E C20H30O2/MF
 L6 17 S E3 AND 5 8 11 14 17
 L7 8 S L6 AND EICOSAPENTAENOIC ACID
 L8 6 S L7 NOT LABELED
 SEL RN
 L9 160 S E1-E6/CRN
 L10 6 S L5,L8

FILE 'HCAPLUS' ENTERED AT 10:56:25 ON 10 MAY 2006

L11 9679 S L10
 L12 652 S ICOSAPENT OR ICOSAPENTAENOIC ACID OR ICOSAPENTAENOATE OR TIMN
 L13 12866 S L4,L11,L12
 L14 100 S L9
 L15 145 S L1-L3 AND L13
 L16 12 S L1-L3 AND L14
 L17 146 S L15,L16
 E ANOREXIA/CT
 E E3+ALL
 L18 2355 S E2,E3
 L19 7622 S ANOREX? OR ANOREX?(S) NERVOSA?
 E BULIMIA/CT
 E E3_ALL
 E BULIMIA/CT
 E E3+ALL
 L20 932 S E1,E2
 L21 1171 S BULIMI?
 E EATING DISORDER/CT
 E E4+ALL
 L22 1983 S E2
 L23 1432 S E1
 L24 4 S L1-L3 AND L18-L23
 L25 1 S L24 AND L17
 L26 3 S L24 NOT L25
 L27 1 S L26 AND 141:105641/DN
 L28 2 S L25,L27
 L29 54 S L17 AND P/DT
 E BODY WEIGHT/CT
 L30 22053 S E3-E5
 E E3+ALL
 L31 64675 S E2 OR E5+OLD,NT OR E6+OLD,NT OR E7+OLD,NT OR E8+OLD,NT
 L32 475 S L13 AND L30,L31
 L33 22 S L32 AND L18-L23

FILE 'REGISTRY' ENTERED AT 11:04:16 ON 10 MAY 2006

L34 1 S 25378-27-2
 L35 17 S 25378-27-2/CRN

FILE 'HCAPLUS' ENTERED AT 11:04:46 ON 10 MAY 2006

L36 1055 S L34 OR L35

L37 2 S L36 AND L18-L23
 L38 30 S L36 AND L30,L31
 L39 2 S L37 AND L38
 L40 22 S L33,L39
 L41 11 S L1-L3 AND L36
 L42 0 S L41 AND L39
 L43 0 S L41 AND L40
 SEL AN L40 4 7-9 12 16-21
 L44 11 S L40 AND E1-E22
 L45 13 S L28,L44
 L46 13 S L45 AND L1-L4,L11-L33,L36-L45

FILE 'REGISTRY' ENTERED AT 11:14:19 ON 10 MAY 2006

L47 STR
 L48 36 S L47 CSS
 L49 756 S L47 CSS FUL
 SAV L49 JONES528/A
 L50 590 S L49 NOT L9,L10

FILE 'HCAPLUS' ENTERED AT 11:21:15 ON 10 MAY 2006

L51 712 S L50
 L52 1 S L51 AND L18-L23
 L53 7 S L51 AND L30,L31
 L54 8 S L52,L53
 L55 0 S L46 AND L51

FILE 'REGISTRY' ENTERED AT 11:24:39 ON 10 MAY 2006

FILE 'HCAPLUS' ENTERED AT 11:24:51 ON 10 MAY 2006

FILE 'MEDLINE' ENTERED AT 11:26:18 ON 10 MAY 2006

L56 2311 S L9 OR L10 OR L50 OR L34 OR L35
 L57 3876 S L4 OR L12
 L58 3877 S L56,L57
 L59 21444 S L19 OR L21
 E ANOREXIA/CT
 E E3+ALL
 L60 2730 S E5+NT
 E E8+ALL
 L61 7839 S E4+NT
 E E3+ALL
 L62 14422 S E3+NT
 E BULIMIA/CT
 E E3+ALL
 L63 4008 S E6+NT OR E11+NT
 L64 22 S L58 AND L59-L63
 L65 9 S L64 AND PY<=2002
 L66 13 S L64 NOT L65
 L67 3 S L66 AND 2003/PY
 L68 12 S L65,L67

FILE 'MEDLINE' ENTERED AT 11:30:07 ON 10 MAY 2006

FILE 'WPIX' ENTERED AT 11:30:21 ON 10 MAY 2006

L69 1082 S L4 OR L12
 L70 57 S EICOSA PENTAEN?
 L71 0 S EICOSA PEN TAEN?
 L72 2 S EICO SAPENTAEN?
 E EICOSAPENTAEN/CN
 L73 9 S E4-E20

```

      SEL SDCN
      EDIT /SDCN /DCN
L74      686 S E1-E10
      SEL DCSE L73
      EDIT E11-E19 /DCSE /DCRE
L75      438 S E11-E19
L76      1355 S L69-L72,L74,L75
L77      4356 S L19 OR L21
L78      4321 S A61P003-04/IPC,IC,ICM,ICS,ICA,ICI
L79      27920 S (B12-J02 OR B14-E12 OR B14-E11? OR C12-J02 OR C14-E12 OR B14-
L80      13 S L76 AND L77
L81      19 S L76 AND L78
L82      168 S L76 AND L79
L83      170 S L80,L81,L82
L84      135 S L69 AND L83
L85      2 S L70,L72 AND L83
L86      135 S L84,L85
L87      35 S L83 NOT L86
      E R04470+ALL/DCN
      SEL AN 30
L88      1 S E1 AND L87
      SEL AN L86 15 46
L89      2 S L86 AND E2-E3
L90      3 S L88,L89 AND L69-L89
```

FILE 'WPIX' ENTERED AT 11:49:37 ON 10 MAY 2006

```

      E R04470+ALL/DCN
      E R13712+ALL/DCN
      E R15961+ALL/DCN
```

=>